Islet Regenerative Properties of Ex Vivo Expanded Hematopoietic Progenitor Cells by Seneviratne, Ayesh K
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
6-20-2014 12:00 AM 
Islet Regenerative Properties of Ex Vivo Expanded Hematopoietic 
Progenitor Cells 
Ayesh K. Seneviratne 
The University of Western Ontario 
Supervisor 
Dr. David Hess 
The University of Western Ontario 
Graduate Program in Physiology 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Ayesh K. Seneviratne 2014 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Biology Commons, Cell and Developmental Biology Commons, and the Endocrinology 
Commons 
Recommended Citation 
Seneviratne, Ayesh K., "Islet Regenerative Properties of Ex Vivo Expanded Hematopoietic Progenitor Cells" 
(2014). Electronic Thesis and Dissertation Repository. 2118. 
https://ir.lib.uwo.ca/etd/2118 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
i 
 
ISLET REGENRATIVE PROPERTIES OF EX VIVO EXPANDED HEMATOPOIETIC 
PROGENITOR CELLS  
 
 
(Thesis format: Integrated Article) 
 
 
 
by 
 
 
 
Ayesh Kumar Seneviratne 
 
 
 
 
Graduate Program in Physiology and Phamacology 
 
 
 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree of  
Master of Science 
 
 
 
 
The School of Graduate and Postdoctoral Studies 
The University of Western Ontario 
London, Ontario, Canada 
 
 
 
 
© Ayesh Seneviratne 2014 
 
 ii 
 
Abstract 
Human umbilical cord blood (UCB) progenitor cells with high aldehyde dehydrogenase 
activity (ALDHhi), can stimulate endogenous islet regeneration after transplantation into mice 
with steptozotocin (STZ)-induced diabetes. However, UCB ALDHhi cell are extremely rare, 
and expansion will be required to develop cell-mediated strategies to treat patients with 
diabetes. To increase the number of progenitor cells available for clinical application, we 
expanded ALDHhi UCB cells under clinically applicable, serum-free hematopoietic-restricted 
conditions. Six day expansion resulted in a 15-fold increase in total cell number, and a 3-fold 
increase in the number of HPC retaining high ALDH (ALDHhi HPC) activity. ALDHhi HPC 
highly expressed primitive hematopoietic cell surface markers, and demonstrated 
hematopoietic colony forming capacity in vitro. Culture-expanded ALDHhi HPC transplanted 
STZ-induced mice demonstrated improved islet function, increased islet size, and 
vascularization. Therefore, culture-expanded ALDHhi HPC represent a novel population for 
the development of cellular therapies to promote islet regeneration.  
Keywords: Aldehyde Dehydrogenase, Hematopoietic Progenitor Cells, Stem Cell Expansion, 
Stem Cell Transplantation, Islet Regeneration, Islet Angiogenesis, Diabetes, Streptozotocin-
treated NOD/SCID mice.  
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1.1 Human Pancreas  
The human pancreas, located in the abdominal cavity behind the stomach, is composed of 
exocrine cells (98%), and endocrine cells (1-2%). The exocrine acinar cells synthesize 
enzymes such as trypsin, chymotrypsin, lipase, and amylase. The synthesized acinar cell 
enzymes as well as bicarbonate secreted by pancreatic ductal epithelial cells, enter the 
duodenum of the small intestine via pancreatic ducts, where these enzymes play an 
important role in digestion.1 In contrast, endocrine cells are clustered throughout the 
exocrine tissue in islets of Langerhans, and synthesize hormones that play an important 
role in glucose homeostasis. 
There are approximately 1 million islets in an adult human pancreas. The islets receive a 
rich vascular supply from the splenic and mesenteric arteries, while the hormones 
synthesized by the islets are secreted into capillaries collected by the portal vein. Pancreatic 
islets consist of four major endocrine cell types: α-cells (35-40%), β-cells (50%), δ-cells 
(10-15%), and pancreatic polypeptide (PP) cells, as well as more recently described 
Epsilon cells.2 α-cells secrete glucagon, a 29 amino acid peptide hormone, when blood 
glucose levels are low. Glucagon then binds to glucagon receptors on hepatocytes to 
increase blood glucose levels, by stimulating the breakdown of glycogen into glucose, and 
the synthesis of new glucose molecules from non-glucose fuel sources. Human β-cells of 
the pancreas sense blood glucose levels via the GLUT1 and GLUT3 glucose transporters, 
and secrete insulin, a 51 amino acid hormone, when blood glucose levels are high.2 Once 
released insulin stimulates insulin responsive cells to uptake, store, and supress the 
production of glucose. δ-cells of the pancreas secretes somatostatin that has potent 
inhibitory effects on insulin, and glucagon release. PP-cells secrete the hormone PP, which 
regulates both endocrine and exocrine secretions.3 Finally, Epsilon cells of the human 
pancreas secrete Ghrelin, which has been shown to stimulate insulin secretion in the rat 
pancreas, however its exact physiological role in the human islet is not known.4        
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1.2 Diabetes Mellitus  
The ancient Egyptian text, the Ebers Papryus written in 552 BC, described a disease that 
caused patients to frequently urinate.5 In 234 BC the Greek physician Aretaeus, named this 
disease diabetes. Diabetes mellitus, as it is now known, is a metabolic disease associated 
with high blood glucose levels. According to the international diabetes federation 382 
million people worldwide currently have diabetes. It is most prevalent in individuals above 
65 years of age, and in people who live in urban areas. With a continued increase in the 
aging population, and increased urbanization, it is predicted that 592 million people will 
have diabetes in the year 2035. There are two main forms of diabetes, type 1 diabetes also 
known as insulin-dependent diabetes mellitus or juvenile onset diabetes, and type 2 
diabetes also known as insulin-independent diabetes mellitus or adult onset diabetes 
(Figure 1.1).  
1.2.1 Type 1 Diabetes  
Type 1 diabetes is an auto-immune disorder where the body’s immune system mediates 
the destructions of insulin secreting β cells of the pancreas.6 Currently, Type 1 diabetes 
accounts for only 5-10% of total diabetic patients, and is the most predominant type of 
diabetes in children. Recent epidemiological data suggest that, the incidence of type 1 
diabetes is increasing worldwide at a rate of 3% a year.6 
Histological analysis has shown that the pancreata of patients with type 1 diabetes have 
lymphocytic infiltration of the pancreatic islets with destruction of insulin producing β 
cells, resulting in an overall decrease in β cell mass. However, α cells, δ cells, and PP cells 
of the islet are intact.7 The inflammatory infiltrate consists of CD8+ and CD4+ T cells, B 
lymphocytes, macrophages, and natural killer (NK) cells.8  
The non-obese diabetic (NOD) mouse model provides insight into the pathophysiology of 
type 1 diabetes. NOD mice spontaneously develop autoimmune diabetes at around 10 
weeks of age.9 Similar to human patients with type 1 diabetes, autoreactive CD4+ and CD8+ 
cells, macrophages, and lymphocytes are detected in the pancreatic infiltrate of NOD 
mice.10 Studies using NOD mice have found that the process of β cell destruction begins 
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when macrophages and dendritic cells present β cell antigens to naïve CD4+ T-cells, using 
the major histocompatibility complex. CD4+ T-cells are then activated.11 In turn, activated 
CD4+ T-cells activate CD8+ T-cells, which are directly responsible for mediating β cell 
death.6 As a result of β cell death additional antigens are released, which permits antigen 
presenting cells further access to self-antigens. Ongoing sampling of these autoantigens, 
leads to the activation of additional auto-reactive T-cells, which results in the amplification 
of the initial autoimmune response.6 Also, the inability of regulatory T-cells to inactivate 
β cell specific autroreactive T-cells contributes to the pathogenesis of type 1 diabetes.12   
Genetic and environmental factors both play a role in the etiology of type 1 diabetes. The 
gene most associated with the risk for type 1 diabetes is the human leukocyte antigen 
(HLA)-DR loci on chromosome 6.13 One in 40 individuals with a HLA-DR3 or HLA-DR4 
at the HLA-DR loci will develop type 1 diabetes. Environmental factors such as diet, cow’s 
milk, protein exposure, vitamin D deficiency, viral infections, drug toxins, and oxidative 
stress are also thought to trigger type 1 diabetes in genetically predisposed individuals.14 
Patients with type 1 diabetes present with weight loss, polyuria, and polydipsia. 
Hyperglycemia, as a result of insulin deficiency, caused by a significant loss of β cell mass 
explains these symptoms.6 Similar to patients with type 1 diabetes, patients with type 2 
diabetes also demonstrate a loss of β cell function, and β cell mass, at the late stages of the 
disease.  
1.2.2 Type 2 Diabetes  
Type 2 diabetes mellitus is a complex metabolic disorder characterized by hyperglycemia, 
insulin resistance-a condition in which cells of the body fail to respond to insulin properly-
and relative impairment in insulin secretion. Type 2 diabetes is the most common type of 
diabetes, as it accounts for 90%-95% of diabetic patients.15 In the past decade, the 
prevalence of type 2 diabetes has risen alarmingly primarily due to an increase in obesity 
and a sedentary life style. Furthermore, it is worrisome that this disease which was 
predominantly found in adults, is now increasingly seen in children and adolescents.15  
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The development of insulin radioimmunoassays in the 1960’s led to the finding that plasma 
insulin levels were often increased in type 2 diabetic patients, and therefore lead scientist 
to believe that the failure to respond to insulin alone could explain the pathogenesis of type 
2 diabetes.16 However, these studies did not measure insulin in the context of insulin 
resistance. As a result, the role of β cell dysfunction in the pathogenesis of type 2 diabetes 
was greatly overlooked.17 Research conducted in the past 15 years has shown that β cell 
inadequacy is a fundamental part of type 2 diabetes. A longitudinal study on 48 Pima 
Indians, showed that β cell dysfunction was prominent in those destined to progress to type 
2 diabetes.18 Multiple measures of insulin sensitivity, and insulin secretion were carried 
out on this very high risk population group. After an average of 5 years, 35% of these 
subjects progressed from normal glucose tolerance, to impaired glucose tolerance, and then 
to diabetes.15 Interestingly, the β cells of the subjects who eventually developed type 2 
diabetes did not secrete enough insulin to overcome insulin resistance, indicating 
diminished β cell function.19 Indeed, the insulin secretion of the subjects that developed 
diabetes declined by 78%, while their insulin sensitivity only decreased by 14%.19 In a 
matched group of subjects who did not develop diabetes, insulin sensitivity declined by 
11%, but insulin secretion increased by 30%.19 In addition, data from the United Kingdom 
Prospective Diabetes Study (UKPDS) that followed 3867 type 2 diabetes patients suggest 
that β cell dysfunction commenced years before overt hyperglycemia developed.20  
The diabetic milieu contributes to both β cell dysfunction, and insulin resistance in type 2 
diabetic patients. Hyperglycemia impairs β cell function by increasing the rate of β cell 
death, via the production of reactive oxygen species.21 An increase in circulating Non-
esterfied fatty acids, is another characteristic of type 2 diabetic patients. Non-esterfied fatty 
acids have been shown to reduce insulin mediated glucose uptake, and impair β cell 
function both in vitro, and in vivo.16,22 The consumption of increased dietary fat triggers 
the deposition of amyloid in pancreas.23  Amyloid plaques in islets are formed by the 
aggregation of islet associated polypeptide (IAPP), and  analysis of pancreas sections of 
type 2 diabetic patients revealed that islets with large amyloid deposits often have fewer β 
cells.24,25 When human IAPP is overexpressed in mice or rats, the result is worsening 
diabetes associated with more amyloid deposition.25 It appears that the toxicity is exerted  
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Schematic representation 
of the mechanisms underlying the pathogenesis of Type 1 and Type 2 diabetes. Type 1 
diabetes is an autoimmune disorder where β cells are destroyed, leading to a reduced β cell 
mass and reduced insulin secretion. Type 2 diabetes is a metabolic disease associated with 
peripheral insulin resistance which reduces the uptake of glucose in tissues, and β cell 
dysfunction which leads to impaired insulin secretion. Although glucose homeostasis is 
impaired by varying mechanisms, both types of diabetes are associated with high blood 
glucose levels.        
Figure 1.1 The mechanisms of Type 1 and Type 2 diabetes. 
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by a specific oligomeric components of the amyloid deposit that can damage cell 
membranes, and increased lipid peroxidation.16         
Genetic predispositions, and environmental factors such as diet, physical activity, and age 
play a large role in the development of the disease.16 Furthermore, certain insults during 
intrauterine fetal growth, such as placental insufficiency, have been associated with the 
fetus developing type 2 diabetes later on in life.26 Since, the exact cause of type 2 diabetes 
is not known, current therapeutic strategies aim to treat the symptoms of the disease.  
1.3 Management of Diabetes  
The symptoms associated with β cell dysfunction in both type 1 and type 2 diabetes are 
treated using exogenous insulin. Furthermore, oral hypoglycemic agents are used to treat 
the peripheral insulin resistance observed in type 2 diabetic patients.   
1.3.1 Insulin Therapy         
Fedrick Banting, Charles Best and John McLeod, demonstrated that intra-venous (i.v.) 
injection of a pancreatic extract from dogs, could reduce blood glucose levels in diabetic 
dogs.5 They called this extract “isletin”, which is now known as insulin.5 After this seminal 
discovery, Banting, Best together with their new team member Collip attempted to increase 
the supply of insulin for human use, by purifying insulin from the pancreas of cattle.5 The 
pancreas extracts from cattle were first administered into Leonard Thompson, a 14 year 
old boy with diabetes, on the 11th of January 1922.5 After the administration of insulin 
injections Leonard’s condition dramatically improved. His blood glucose, and glucosuria 
decreased, and his ketouria disappeared.27 Similar outcomes were archived when insulin 
was administered to six other diabetic patients.5 
Many advances to insulin have been made since its initial discovery in 1922. Eli Lily and 
August Krogh worked independently to improve the extraction and purification of insulin 
from animal sources. In the 1930’s protamine and zinc were added to animal insulin to 
prolong its action.28 Then in 1978 the first human synthetic insulin was prepared by David 
Goeddel and his colleagues at Genentech.5 The rapid and the short acting forms of synthetic 
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insulin were marketed under the brand names Humulin R and Humulin NPH respectively.5  
The discovery of insulin dramatically increased the life expectancy of diabetic patients. 
Before the discovery of insulin the average life expectancy in diabetic patients was 6.1 
years from diagnosis. Soon after insulin therapy became available to the general public the 
average life expectancy of a diabetic patient increased to 18.2 years after diagnosis. 
Now with advances such insulin pumps, and continuous blood glucose monitoring systems 
both type 1 and type 2 diabetic patients can be managed more effectively.15 However, since 
type 2 diabetic patients also demonstrate insulin resistance, additional pharmacological 
agents are required to manage this disease. Even with modern insulin therapies and 
pharmacological agents, the life expectancy of diabetic patients is reduced by 15 years.  
1.3.2 Pharmacological Agents  
Currently, patients presenting with type 2 diabetes symptoms are initially managed using 
oral antidiabetic agents. These agents act through a variety of mechanisms to achieve 
euglycemia. The American Diabetes Association, and the European Association for the 
study of diabetes recommends a patient-centered approach with respect to medication 
choices. When initiating pharmacological treatments, Metformin seems to be the drug of 
choice, unless it is not tolerated by the patient.29 Metformin reduces blood glucose levels 
in type 2 diabetic patients by reducing gluconeogenesis in the liver.30 Similar to Metformin, 
Thiazolidinediones also reduce gluconeogenesis in the liver.31 Specifically, 
Thiazolidinediones re-direct fat from the liver to subcutaneous adipose depots, thereby 
improving insulin sensitivity in the liver. In contrast, Sulfonylureas lowers blood glucose 
levels by stimulating insulin secretion from β cells.32 Type 2 diabetic patients also have 
elevated triglyceride levels, which is a risk factor for cardiovascular disease. In addition to 
lowering plasma blood glucose levels, the D2-dopamine agonist Bromocriptine reduces 
plasma triglyceride and free fatty acid levels without increasing plasma insulin levels.33 
However, it has been documented that approximately 25% of type 2 diabetic patients do 
not respond sufficiently to the available therapies.29  
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1.4 Diabetes Complications 
Even with current insulin and drug therapy more than 90% of diabetic patients develop 
long-term vascular complications.34 Diabetic vascular complications are grouped under 
either microvascular or macrovascular disease. Microvascular complications arise due to 
damages in small blood vessels, and includes: eye disease or retinopathy, kidney damage 
or nephropathy, neural damage or neuropathy.35 The major macrovascular complications 
include: accelerated cardiovascular disease resulting in myocardial infarction, and 
cerebrovascular disease manifesting as strokes.35 The chronic elevation in blood glucose 
levels is suggested to give rise to vascular complications by either damaging the cells of 
the affected organs, or damaging the blood vessels that supply the affected organs. The 
progression of these complications can be slowed but not stopped with aggressive 
management of glycemia and blood pressure, laser therapy for advanced retinopathy, and 
the administration of an angiotensin converting enzyme inhibitor or angiotensin receptor 
II blocker for nephropathy.35 Thus, to prevent the morbidities associated with these 
complications curative therapies that re-establish a functional β cell mass are currently 
under intense investigation.36 
1.5 Whole Pancreas Transplantation 
Transplantation of cadaveric pancreata is performed in patients with type 1 diabetes, type 
2 diabetes, and those who have undergone a total pancreatectomy.37 The first pancreas 
transplant was performed in 1966 by William Kelly and Richard Lihelli at the University 
of Minesota, USA.38 Since then, >27,000 pancreas transplants have been performed in the 
United States of America.37 Over the years pancreas transplants have evolved from 
experimental procedures to the standard of care for patients with severe diabetes mellitus 
and uremia.37 Pancreas transplants are performed on three major categories of patients: 1) 
patients with uremia who undergo simultaneous pancreas and kidney transplants, 2) 
patients who are posturemic who undergo a pancreas transplant after a kidney transplant, 
3) patients with brittle diabetes without uremia who undergo a pancreas transplant alone.37 
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Overall the average graft survival, defined by insulin independence, was >96% 1 year post 
transplant, and > 80% at 5 years.39 The time it takes to lose 50% of graft function ranges 
from 7-14 years. Furthermore, a successful pancreas transplant seem to be a lot more 
effective than intensive insulin therapy at lowering levels of HBA1c.40,41 Even 10 years 
after transplantation, a successful pancreas transplant can preserve insulin secretion and 
provide good glycemic control.  
1.6 Islet Cell Transplantation 
Islet cell transplantation is an alternate strategy that can be used to re-establish functional 
β cell mass in severely diabetic patients. This procedure is gaining popularity, because of 
the relatively low perioperative risks associated with islet cell transplantation when 
compared to pancreas transplantation.42 The first attempt at islet transplantation was made 
by Watson-Williams and Harsant in 1893, when they transplanted minced sheep’s pancreas 
into the subcutaneous tissue of young boy with ketoacidosis.43 After the discovery of 
insulin the interest in islet transplantation dwindled, but was renewed in 1972 when Drs. 
Ballinger and Lacey demonstrated a method for isolating intact islets of Langerhans from 
rodents that retained function after transplantation into a rodent model of diabetes.44 
Twenty years later Scharp et al.45 was able use the islet transplantation methodology to 
achieve insulin independence in a human diabetic patient for nearly 1 month. Further 
advances and experimentation contributed to the development of the Edmonton protocol 
in the year 2000. In this procedure, islets were procured from multiple (2-4) deceased 
donors, purified, and then infused percutaneously into the portal vein of the recipient. 
Furthermore, this is the first protocol that did not use steroid-based immunosuppressant 
therapy due to its toxic effect on β cells. One-hundred percent of the recipients achieved 
insulin independence after one year of transplantation, and none experienced severe 
hypoglycemic episodes.46 However, continued autoimmune destruction of donor islets, the 
need for life-long immunosuppressant therapy, and the critical shortage of donor pancreata 
limits the use of this procedures.36  
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1.7 Stem Cells 
Due to the limitation of current β cell replacement therapies, methods of utilizing stem cells 
to establish functional β cells for transplantation are being studied. Stem cells play an 
important role in the development and regeneration of tissue and organ systems.47 These 
cells have two distinguishing features, the ability to self-renew through cell division, and 
the ability to differentiate into multiple cell types with specialized function.48 There are 
three main types of stem cells: (1) Embryonic stem cells (ESC), (2) induced pluripotent 
stem cells (iPSC), (3) adult stem cells (Figure 1.2).  
1.7.1 Embryonic Stem Cells  
ESC are derived from the inner-cell mass of 4-5 day old mouse or human blastocyst. These 
cells are termed pluripotent, thereby have the ability to give rise to any of the 3 germ layers, 
ectoderm, mesoderm, and endoderm.49 Martin Evans was the first to isolate and culture 
mouse embryonic stem cells (mESC).50 To maintain pluripotency in vitro, Evans cultured 
mESC on a feeder layer of division incompetent mouse fibroblast (MEF). Seventeen years 
later the first human embryonic stem cells (hESC) was established, by Jamie Thompson.51 
Similar to mESC, hESC were maintained in vitro by embryonic fibroblast feeder cells. The 
establishment of hESC provide exciting prospects for cellular therapies. Currently, 
researchers are attempting to differentiate human hESC into cell types of a wide range cell 
lineages, to treat diseases associated will cellular deficiency.49  
1.7.2 Induced Pluripotent Stem Cells 
Induced pluripotent stem cell (iPSC) has flourished, as a result of the controversies 
surrounding hESC research. iPSC were first generated by Shinya Yamanaka in 2007, by 
expressing the transcription factors Oct4, Sox2, KLF4, and c-myc through retroviral 
transduction in human skin fibroblasts.52 Similar to hESC, iPSC are pluripotent, and 
thereby have the ability to differentiate into cells of all three germ layers of the body. iPSC 
are currently used as tools for drug development, and modeling diseases. However, 
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transduction using retroviruses may cause insertion mutagenesis, and subsequent adverse 
effects such as cancer.53 Therefore, researchers are currently attempting to generate 
retroviral free induction methods in order to generate iPSC that can be used in 
transplantation medicine.54–58 
1.7.3 Adult Stem Cells 
Currently, there are few therapies using hESC or iPSC despite the promise that these cells 
offer. This is due to difficulties of directing the production of a functional effector cells, 
and their potential for teratoma forming capacity. In contrast, adult stem cells are safely 
used in the clinic for a number of medical procedures including bone marrow (BM) 
transplantation to treat hematological malignancies.   
Adult stem cells, also known as somatic stem cells, are undifferentiated cells found among 
differentiated cells within an organ. These cells are usually considered multipotent, since 
they have the ability to differentiate into mature cells of a particular lineage, or germ layer. 
The physiological role of adult stem cells is organ maintenance and repair, by replenishing 
damaged or dying cells, so that organ function is maintained. Adult stem cells have been 
identified in almost every organ in the human body including: the brain, BM, umbilical 
cord blood (UCB), blood vessels, skeletal muscle, skin, gastro intestinal tract, liver, ovarian 
epithelium, and testes. Of these many types of adult stem cells, hematopoietic stem cells 
(HSC) which are derived from adult BM or UCB are extremely well characterized.   
1.7.3.1 Hematopoietic Stem Cells 
HSC demonstrate the ability to self-renew, and differentiate into specialized blood cells of 
both the myeloid and lymphoid lineages. The initial evidence for the existence of HSC 
came in the atomic era. It was found that the lethal consequences of radiation was due to 
BM failure, and that this condition could be rescued following injection of spleen or BM 
cells from unirradiated donors.59 The study of HSC moved from observational to functional 
when landmark by Till and McCulloch showed that the regenerative potential of HSC could 
be assayed using clonal in vivo repopulation assays, thus establishing the existence of a 
multipotential HSC.60 Xenotransplantation assays were used to functionally characterize  
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Figure 1.2 Differentiation Potential of Stem Cells. Schematic of the differentiation 
potential of embryonic stem cells stem (ES) cells, induced pluripotent stem (iPS) cells, and 
adult stem cells. ES cells, iPS cells, and adult stem cells all possess the ability to self-renew, 
and differentiate. However, ES and iPS cells are pluripotent thereby can differentiate into 
cells of all three germ layers. Whereas, adult stem cell such as hematopoietic stem cells 
(HSC) are germ-layer specific in their differentiative ability.   
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human HSC, and still remain the gold standard. The multipotency of HSC was 
demonstrated by the ability of human HSC to repopulate the myeloid and lymphoid 
compartment of the BM of an irradiated immunodeficient mouse.47,61 The self-renewal 
potential of human HSC has been demonstrated by the ability of a single HSC to repopulate 
the BM of a primary host, and give rise to other HSC that can reconstitute all blood lineages 
in secondary hosts.47 In contrast, the most immediate progeny of HSC, hematopoietic 
progenitor cells (HPC), loose their capacity for self-renewal, and therefore were unable to 
reconstitute the BM of a secondary host.47,61     
Cell surface molecules expression as HSC mature during hematopoiesis is a highly 
regulated, and conserved process (Figure 1.3).62 For instance, early HSC and HPC express 
the cell surface antigens CD34 CD133 and do not express CD38.63 Whereas, the more 
lineage committed cells such as: myeloid progenitors, early thymic progenitors, and B/NK 
cell progenitors do not express CD133, and express both CD34 and CD38. Finally, the 
mature effector cells of the lymphoid, and myeloid lineage express lineage specific 
markers, but do not express CD34 or CD38.61 Fluorescent monoclonal antibodies (CD34, 
CD38, and CD133), and fluorescence activated cell sorting (FACs) can be used to separate 
HSC and HPC populations (HSC/HPC) from more mature lineage committed cells (Lin+).  
However, considerable controversy exists regarding the expression of CD34 on true HSC. 
Bhatia et al.64 demonstrated that CD34-/CD38- cells isolated from UCB depleted of mature 
lineage committed cells (Lin-) were functionally distinct from UCB Lin-/CD34+ HSC/HPC, 
and these cells had the ability to initiate multilineage hematopoiesis in non-obese diabetic 
severe combined immunodeficient (NOD/SCID) mice. It has also been reported that, UCB 
Lin-/CD34- cells can generate CD34+ cells once transplanted into NOD/SCID mice.65 A 
recent study showed that, Lin-/CD34-/CD38-/CD93+ UCB cells initiated multilineage 
hematopoietic engraftment in both primary, and secondary hosts.66 Lin-/CD34-/CD38-
/CD93+ UCB cells were highly quiescent, compared to Lin-/CD34+/CD38- cells. 
Furthermore, the progeny of Lin-/CD34-/CD38-/CD93+ cells, were more efficient at 
engrafting to a secondary host, compared to the progeny of Lin-/CD34+/CD38- progenitor 
cells. Suggesting that, Lin-/CD34-/CD38-/CD93+ cells are more primitive than Lin-
/CD34+/CD38- cells.                      
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Alternatively, HSC/HPC can be isolated according to stem cell function, rather than 
phenotype. In order to facilitate the daily production of approximately one trillion (1012) 
blood cells in the human body, the HSC/HPC pool must be maintained throughout the life 
of the organism.61 Thus, enzymes such as aldehyde dehydrogenase (ALDH) that protects 
against reactive aldehydes, and reactive oxygen species (ROS) are highly expressed in 
HSC/HPC.67 In contrast, more mature blood effector cells have low ALDH activity (Figure 
1.3). There are 19 structurally related ALDH isoforms in humans, and 20 ALDH isoforms 
have been described in mice.68 Out of these isoforms ALDH1A1 is the most abundantly 
expressed in HSC/HPC, but ALDHA1 knockout did not adversely affect HSC/HPC 
function.69 Interestingly, ALDH1A1 knockout was associated with an increase in 
ALDH3A1 in the HSC/HPC pool, suggesting this enzyme compensates for the loss of 
ALDH1A1. The HSC/HPC pool in mice deficient in both ALDH1A1 and ALDH3A1, have 
an increased ROS level, and are more sensitive to DNA damage. As a result, ALDH1A1 
and ALDH3A1 deficient mice have reduced HSC/HPC cell numbers. In addition, 
ALDH1A1 and ALDH3A1 deficient mice had deficiencies in B cell development. Thus, 
this study illustrates that ALDH plays an important role in B cell development and 
HSC/HPC survival.   
In addition, ALDH1A1 is a critical enzyme in the biosynthesis of retinoic acid (RA), the 
active metabolite of vitamin A (retinol).68 ALDHA1 catalyzes the oxidation of 
retinaldehyde to retinoic acid, the final step in this process.70 RA, is a non-peptidic 
lipophilic morphagen that enters the nucleus, and binds to the heterodimer formed by the 
RA receptor (RAR) and the retinoid-x-receptor (RXR) to drive the transcription of target 
genes.70 Human HSC/HPC are intrinsically programmed to undergo differentiation in 
response to RA, since HSC/HPC highly express ALDHA1 and RARα. Human BM stromal 
cells highly express CYP26 enzymes inactivates retinoids, and thereby maintains an 
environment low in retinoids in the human BM.  Culturing HSC/HPC ex vivo both in the 
presence and absence of retinoic acid resulted HSC/HPC differentiation.70,71 Furthermore, 
blocking the RAR receptor or ALDHA1 during ex vivo culture prevented HSC/HPC  
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Figure 1.3 Adult Human hematopoietic hierarchy. Schematic representation of the 
phenotypic markers expressed by hematopoietic stem/progenitor cells (HSC/HPC) and 
mature blood cells (adapted from Doulatov et al.61) The expression of cell surface 
molecules as HSC mature during hematopoiesis is a highly regulated process. Therefore, 
cell surface markers can be used to separate more primitive HSC/HPC cells from more 
mature lineage committed blood cells. Alternatively, HSC/HPC can be isolated according 
to stem cell function via relative aldehyde dehydrogenase (ALDH) activity. HSC/HPC 
have high ALDH activity, whereas more committed cells have low ALDH activity. 
Myeloid progenitor (CMP), Lymphoid progenitor (CLP), T cell progenitor (CTP), B cell 
progenitor (CBP), NK cell progenitor (NKP), granulocyte/macrophage progenitor (GMP), 
megakaryocytic/erythroid progenitor (MEP).     
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differentiation, and promoted HSC/HPC self-renewal.70,71 These studies suggest that, 
retinoids play an important role in mediating key aspects of HSC self-renewal and 
differentiation.                            
The fluorescent substrate for ALDH, BODIPY aminoacetaldehyde developed by Storms 
et al.,72 and now marketed as Aldeflour™ by Stem Cell Technologies™ can be used to 
detect relative ALDH activity. Aldeflour™ is a aminoacetadehyde moiety conjugated to a 
BODIPY (4,4-difluoro-5,7-dimethyl-4-bora-3a,4adiaza-5-proprionic acid) flourochrome. 
Once the lipophilic Aldeflour™ substrate enters the cells it is converted to an acetaldehyde 
anion by ALDH. Under pharmacological inhibition of ABC transporters with the 
Aldeflour™ buffer, cells with high ALDH activity retain a higher amount of Aldeflour™ 
compared to cells with low ALDH activity. Thereby, cells with high ALDH activity will 
be brighter compared to cells with low ALDH activity, a property that enables the FACS 
purification of these two populations 72,73. The integrity and function of the cell are not 
compromised by this procedure since upon removal of the Aldeflour™ buffer the ABC 
transporter becomes reactivated and Aldeflour™ is pumped out of the cell returning the 
cell to its original state, thus the isolated cells can be used for various downstream 
applications.  
Hess et al.,73 showed that, UCB progenitor cells with high ALDH (ALDHhi) activity 
isolated from Lin- UCB have enhanced in vitro colonergic progenitor activity, and highly 
co-express primitive hematopoietic cell phenotypes compared to UCB cells with low 
ALDH (ALDHlo) activity. Furthermore, transplantation of Lin-/ALDHhi UCB progenitor 
cells into NOD/SCID and NOD/SCID β2 microglobulin (β2M) null mice resulted in 
multilineage human cell engraftment in hematopoietic tissues, while Lin-/ALDHlo UCB 
cells were devoid of repopulation ability.74 Further dissection of the Lin-/ALDHhi UCB 
progenitor population by using the cell surface molecule CD133 showed that, Lin-
/ALDHhi/CD133+ progenitor cells are significantly enriched for in vivo repopulating ability 
compared to Lin-/ALDHhi/CD133- progenitor cells. Limiting dilution analysis 
demonstrated that, Lin-/ALDHhi/CD133+ cells have a 10-fold increase in the frequency of 
NOD/SCID repopulating cells (also known as SCID repopulating cells, SRC) compared 
with Lin-/CD133+ cells. Furthermore, the hematopoietic and non-hematopoietic progeny 
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of ALDHhi UCB trafficked efficiently to various organs including the pancreas after being 
transplanted into glucuronidase (GUSB)-deficient NOD/SCID/mucopolysaccharidosis 
type VII mice (MPSVII) mice. Therefore, Aldeflour™ can be used to isolate HSC/HPC. 
1.7.3.2 Ex vivo Expansion of Hematopoietic Stem and Progenitor 
Cells 
The widespread initiatives to HLA-phenotype and cryopreserve human UCB in North 
America and Europe, has ensured that UCB represents a readily available source of 
HSC/HPC for cell therapy applications. However, the low number of HSC/HPC found in 
UCB limits the widespread therapeutic application of transplanted UCB-derived HSC/HPC 
in humans.75,76 Therefore, ex vivo expansion of HSC/HPC is one of the ways which the 
number of UCB can be increased for cellular therapies.  
The last two decades, researchers have established protocols aimed at the ex vivo expansion 
of HSC/HPC for clinical application.75 Under serum free conditions, hematopoietic 
cytokines are necessary for amplification HSC/HPC ex vivo.77,78 These signaling 
molecules, are produced by stromal cells in the bone marrow, and induce the proliferation 
of hematopoietic cells at various stages of development.76 The rapid discovery of new 
hematopoietic growth factor’s and their receptors enabled researchers to find cytokines that 
amplified HSC/HPC in culture.76 Initially HSC/HPC expansion was supported by 
hematopoietic cytokines and serum. Since, serum is a potential source of bacterial, 
mycoplasmas, and viral contaminants, many investigators attempted to develop serum free 
conditions to expand HSC for clinical application.79 Through systematic analysis it was 
found that stem cell factor (SCF), fms-related tyrosine kinase 3 ligand (FLT-3L), and 
thrombopoietin (TPO) were essential cytokines for the expansion of primitive progenitor 
cells in serum-free culture.77,78 In contrast, the addition of other cytokines such as: 
interleukin-3 (IL-3), granulocyte colony stimulating factor (G-CSF), erythropoietin (EPO) 
and macrophage colony-stimulating factor (M-CSF) supports the expansion of more 
mature hematopoietic cells, instead of primitive HSC/HPC.80,81 Furthermore, research has 
also established that the selection of a purified starting cell population is a key aspect in ex 
vivo expansion protocols. ALDHhi, CD34+/CD38-, CD34+/CD133+ progenitor cells 
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demonstrate a greater expansion potential than their more heterogeneous cell populations 
containing mature cell counterparts.82–88 At the single cell level, multipotent progenitor 
cells can give rise to 70×106 nucleated cells, and more than 90,000 CD34+ progenitor cells, 
whereas mature erythroid progenitors can only produce 9×106 nucleated cells and no more 
than 5,000 CD34+ progenitor cells.89 Currently, researchers are attempting to improve ex 
vivo expansion technologies to increase the number of HSC/HPC available for cellular 
therapies.85,90–102  
1.8 Stem Cell Therapies for Diabetes  
There are two major initiatives in the stem cell biology field to correct the loss of β cell 
mass in both type 1, and type 2 diabetic patients: (1) generating β cells ex vivo, by utilizing 
pluripotent stem cells; (2) stimulating the regeneration of β cells in the pancreas using adult 
stem cells.36   
1.8.1 β Cell Replacement  
1.8.1.1 Derivation of β cells from ESC  
A number different groups are attempting to differentiate ESC’s and iPSC’s into functional 
β cells, to provide an unlimited source of β cells for replacement therapy in diabetic 
patients.36 In order to generate glucose responsive pancreatic β cells from hESC, critical 
signals that regulate endocrine pancreas development needs to be successfully 
recapitulated in vitro. During normal development human epiblast cells first differentiate 
into definite endoderm during gastrulation. Culturing hESC in Wnt3a and activinA leads 
to cultures that contain 80% definitive endodermal cells.103,104 Attempts to efficiently 
produce β cells from the definitive endoderm has not been as fruitful. In 2005 Novocell 
(now Viacyte) developed a complex multi-step protocol to generate insulin-producing β 
cells. However, only 7.3% of the cells generated using this protocol were positive for 
insulin.105 By making modification to the Viacyte protocol Nostro et al.106 was able to 
increase the number of insulin-producing cells to 25%. In both these protocols the insulin 
producing cells were polyhormonal, and were not glucose responsive. Alternatively, Kroon 
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et al.107 differentiated hESC into pancreatic-endocrine progenitor like cells in culture, and 
subsequently transplanted these progenitor cells into streptozotocin induced (STZ)-diabetic 
mice. Following transplantation, the endocrine progenitor-like cells matured into various 
cell types, including functional β cells that normalized the blood glucose levels of these 
diabetic mice. Although, these results were very encouraging, the composition, 
organization, and mass of the resulting cellular structure from progenitor cell 
differentiation in vivo was highly unpredictable.108 Furthermore, signals that stimulate 
endocrine progenitor cells to differentiate into fully functional β cells remain unknown.108 
Thus, the inability to differentiate hESC into functional β cells in culture, coupled with 
ethical concerns and tumorigenicity of hESC-derived β cells, has prevented the use of 
hESC-derived β cells in a clinical setting.  
1.8.1.2 Derivation of β cells from iPSC 
Similarly, iPSC can be used as a non-embryonic source for the derivation of β-like cells. 
Murine iPSC–derived β-like cells have the capacity to normalize hyperglycemia in both a 
type 1 and type 2 diabetic mouse models.109 Furthermore, iPSCs derived from the epiblast 
of non-obese diabetic (NOD) mice differentiated into insulin-producing cells that 
expressed diverse pancreatic β cell markers, and normalized hyperglycemia upon 
transplantation into diabetic mice.110 In another study, human iPSCs derived from dermal 
fibroblasts of patients with type 1 diabetes, were differentiated into cells that expressed 
insulin, somatostatin, and glucagon in vitro.111 Interestingly, these cells were able to 
produce insulin in response to glucose.111 Thus, iPSCs may be an appropriate choice for 
generating autologous β cells, however like hESC, the clinical utility of iPSC is hampered 
by incomplete maturation of differentiated cells, chromosomal aberrations, and enhanced 
tumorigenic potential.112 Due to these limitations, strategies that stimulate endogenous islet 
regeneration in situ are also under intense investigation.      
1.8.2 Endogenous Islet Regeneration Therapies  
The β cell mass in adult humans is maintained at a constant level with very low cellular 
turnover.113 Interestingly, drastic increases in β cell mass have been observed in response 
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to the increase in metabolic demand during pregnancy and obesity.114–116 Studies in mice 
have attempted to elucidate the mechanism that induces β cells to re-enter the cell cycle. 
Factors such as epidermal growth factor (EGF), insulin-like growth factor 1 (IGF1), human 
growth hormone, prolactin, as well as glucose have been shown to stimulate β cell 
proliferation in the mouse.117 In Hess and collegues118  initial publication on islet 
regeneration, they showed that transplanted murine BM progenitor cells reduced 
hyperglycemia in STZ-induced NOD/SICD (STZ-NOD/SCID) diabetic mice.118 
Transplanted BM progenitor cells engrafted in the ductal and islet regions of the damaged 
pancreas, but did not differentiate into insulin producing cells. Instead, BM progenitor cells 
stimulated β cell proliferation, and enhanced insulin production in recipient-derived islets 
via undetermined mechanisms.118 In order for endogenous islet regeneration to be a feasible 
strategy, the signal receiving cells within the pancreas, and the mechanism by which 
transplanted cells stimulate β cell expansion needs to be identified.  
1.8.2.1 The Medalist Study 
The medalist study followed 411 type 1 diabetic patients with disease duration of more 
than 50 years.34 The majority (63.4%) of the medalist had c-peptide levels in the minimal, 
and sustained range.34 Furthermore, their c-peptide release doubled during a mixed meal 
tolerance test.34 Histological analysis of pancreas sections, from the patients that died 
during the study showed the presence of insulin+  proliferating β cells.34 The data presented 
in this study clearly supports that, residual functional β cells can remain in type 1 diabetic 
patients with long standing diabetes. Thus, the amelioration of autoimmune destruction of 
β cells, together with stimulating the regeneration of endogenous β cells, may represent a 
feasible approach to improve endogenous insulin production in patients with type 1 
diabetes. In order to develop better therapies to stimulate islet regeneration, the activation 
of endogenous regenerative mechanisms within the pancreas must be understood.   
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1.8.2.2 Mechanisms of Endogenous Islet Regeneration 
The mechanisms by which new β cells arise in the post-natal pancreas is highly 
controversial, and is still under intense research (Figure 1.4). To investigate the origin of 
adult β cells, Dor et al.119 performed a pioneering lineage tracing experiment. These 
researchers defined mature β cell as post-natal cells transcribing the insulin gene, and used 
a pulse-chase lineage tracing approach to distinguish stem-cell derived β cells, from the 
progeny of pre-existing β cells. Firstly, pre-existing mouse β cells were heritably labelled 
with tamoxifen-inducible Cre transgene, rat insulin promoter (RIP)-CreER, and a human 
alkaline phosphatase reporter (HAP, the pulse). Then the labelled cells (HPAP+) were 
tracked over a period of time or after injury, during which cellular turnover occurred (the 
chase). Using this approach, the cells generated from pre-exiting β cells are labelled, but 
new β cells derived from any other cells, including stem cells will not be labelled. Thus, if 
new islets are derived entirely from stem cells, these islets would not contain any labeled 
β cells. If stem cells replenish β cells within existing islets, the frequency of labelled β cells 
would gradually decrease. However, if new β cells are derived from pre-existing β cells the 
frequency of labelled β cell within an islet would remain constant. Interestingly, over time 
and after injury the total number of β cell increased, but the frequency of labelled β cells 
remained constant.119 Thus, it was concluded that β cell expansion was primarily driven by 
the division of already differentiated cells.  
However, Dor et al.119’s definition of a mature β cell has been questioned by the recent 
identification of a rare population of insulin expressing cells in the murine and human 
pancreas that have progenitor like characteristics.120,121 These cell referred to as pancreas-
derived multipotent progenitor (PMP) cells, are able to form colonies in vitro and 
differentiate into all hormone producing cells in the endocrine pancreas. Furthermore, 
transplantation of both murine and human PMPs improved hyperglycemia in STZ-diabetic 
mice.120,121 Thus, it is possible that these insulin+ precursors also contributed to the increase 
in the number of β cells observed by Dor et al.119 Further research is required to delineate 
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the relative contributions of mature β cells and β cell precursors during β cell expansion 
after injury, and during adult life.   
In contrast, endogenous islet regeneration has been shown to occur through the activation 
of ductal-resident progenitor cells that may contribute to new islet formation. Inada et al.122 
used a lineage tracing approach to determine if ductal progenitors gives rise to β cells after 
ductal ligation in the adult pancreas. These researchers used the reporter gene β-
galactosidase (β-gal) to trace carbonic anhydrase II+ ductal cells. After ductal ligation, the 
number of β-gal+ β cells increased, which suggests that islet regeneration occurs through 
the differentiation of ductal cells, into insulin expressing β cells. Furthermore, Xu et al.123 
used pancreatic ligation as an injury model, and a neurogenin 3 (Ngn3) reporter to trace 
Ngn3+ endocrine precursor present in the ducts. Upon injury, these cells were activated in 
the ducts and could give rise to all endocrine cell types in situ, and in embryonic explant 
cultures. These studies suggests that the islet neogenic program may also be activated after 
pancreas injury.  
In addition, Rovira et al.124 showed that adult mouse ALDH+ centroacinar and terminal 
duct (CA/TD) cells highly express progenitor cell markers Sca1, Sdf1, c-Met, Nestin, and 
SOX9. Notably, these ALDH+ CA/TD cells were able to form pancreatosphere colonies 
in vitro, that demonstrated spontaneous endocrine and exocrine differentiation, as well as 
glucose responsive insulin secretion. When ALDH+ CA/TD cells were injected into mouse 
embryonic dorsal pancreatic buds these cells also differentiated into both endocrine and 
exocrine lineages. Finally, ALDH+ CA/TD cells in the pancreas expanded in the setting of 
chronic epithelial cell injury. In addition, Li et al.125 showed that ALDH+ human fetal 
pancreas cells highly express progenitor cell markers. High ALDH expression was 
observed in newly differentiated insulin+ cells, and overall ALDH-expression was 
decreased as development progressed. Interestingly, pharmacological inhibition of ALDH 
activity resulted in reduced endocrine cell differentiation, which was reversed by with co-
treatement of an RAR/RXR agonist. Collectively, these studies suggest that ALDH+ cells 
represent a pool of progenitors that may contribute to the maintenance of pancreatic tissue 
homeostasis in the adult mouse and human fetal pancreas.  
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Figure 1.4 Mechanisms of endogenous islet regeneration in the post-natal pancreas. 
Schematic representation of the proposed mechanisms of endogenous islet regeneration 
(adapted from Bonner-Weir et al.36). The proliferation of pre-existing β cells and the 
differentiation of intra-islet pancreas-derived multipotent progenitor (PMP) cells has been 
shown to give rise to new β cells. Alternatively, islet neogenesis, via the differentiation of 
Ins+, Ngn3+, and CAII+ ductal progenitor cells and ALDH+ centroacinar and terminal  
ductal (CA/TD) progenitor cells has also been implicated in restoring β cells.  
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Although, research is required to delineate the mechanism of endogenous islet 
regeneration, finding a therapeutic strategy that “tips the balance” in favour of islet 
regeneration versus destruction will be beneficial therapeutic strategy to treat diabetic 
patients.    
1.8.2.3 Blood Progenitors Stimulate Endogenous Islet Proliferation 
and Revascularization 
Bell et al.’s126,127 studies provide insight into the potential mechanisms by which BM and 
UCB derived human progenitor cells stimulate endogenous islet regeneration (Figure 1.5). 
Bell and colleagues found that, i.v. transplantation of BM derived ALDHhi progenitor cells, 
and not ALDHlo BM cells improved systemic hyperglycemia and augmented insulin 
production in STZ-NOD/SCID diabetic mice.126 In addition, only certain Multipotent 
Stromal (MSC) samples derived from BM improved the islet function of STZ-NOD/SCID 
diabetic mice. Interestingly, the islet regenerative program activated depends on the 
lineage-restriction of the progenitor cell administered. ALDHhi progenitor cells derived 
from BM engrafted around the damaged islets, and secreted paracrine factors to stimulate 
islet specific-vascularization and islet-associated cell proliferation. This resulted in an 
increase islet size (islet circumference), and β cell mass. In contrast, i.v. transplanted MSC 
did not engraft in the pancreas or stimulate islet proliferative or pro-angiogenic programs. 
Instead, MSC improved systemic hyperglycemia by stimulating the formation of β cell 
clusters associated with cytokeratin (CK19) + ductal epithelium, which resulted in an 
increase in islet number, suggestive putative neogenic mechanism, whereby MSC stimulate 
CK19+ cells to differentiate into insulin+ β cells. 
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Figure 1.5 Endogenous islet regeneration after the transplantation of human 
BM/UCB-derived ALDHhi progenitor cells or BM-derived MSC. Schematic 
representation of mechanisms involved in islet regeneration after the transplantation of 
progenitor cells (adapted from Bell et al.128). Transplantation of ALDHhi cells augmented 
islet size and vascularization, by stimulating β cell and endothelial cell proliferation, but 
did not increase islet number. Transplantation of MSC induced an increase in β cell clusters 
associated with CK19+ ducts, which also resulted in an increased β cell mass. Thus, the 
islet regenerative program activated depends on the lineage restriction of the progenitor 
cell administered.  
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In addition, ALDHhi progenitor cells isolated from UCB stimulated endogenous islet 
regeneration. Intravenously injected ALDHhi UCB progenitor cells demonstrated low-
pancreas engraftment, and only transiently improved islet function.127 Whereas, intra-
pancreatic (iPan) transplantation ALDHhi UCB progenitor cells, and not ALDHlo UCB 
cells improved systemic hyperglycemia, augmented insulin production, and improved 
glucose tolerance in STZ-NOD/SCID diabetic mice. Similar to ALDHhi progenitor cells 
isolated from the BM, iPan transplanted ALDHhi UCB cells surrounded the damaged 
pancreas, and stimulated the islet associated-cell proliferation and islet angiogenesis.126,127   
To identify paracrine effectors secreted by ALDHhi UCB that stimulated islet regeneration, 
the mRNA transcripts of islet regenerative ALDHhi UCB cohort was compared to the non-
regenerative ALDHlo UCB cohort.128 ALDHhi UCB highly expressed the ligands of the 
epidermal growth factor receptor (EFGR) superfamily amphiregulin (AREG), epiregulin 
(EREG). The EGFR superfamily has been implicated in the regulation of pancreatic β cell 
mass. Also, EGFR signaling was essential for the β cell mass expansion in response to a 
high fat diet or pregnancy. Furthermore, ALDHhi UCB highly expressed pro-angiogenic 
cytokines such as angiopoietin 1 (ANGPT1) and vascular endothelial growth factor A 
(VEGF A). In contrast, islet regenerative MSC highly expressed the transcripts of fibrillin 
2 (FBN2)-a modulator of transforming growth factor β (TGFβ) bioavailability-WISP1 
(WNT1 inducible signaling pathway protein 1) and SFRP1 (Secreted frizzled-related 
protein 1)-matrix modifiers downstream of WNT-signaling. Both the TGFβ signaling, and 
WNT-signaling are required for pancreatic lineage development. This study suggests that, 
AREG, EREG, VEGF and ANGPT1 are involved in supporting β cell proliferation, and 
islet angiogenesis. Whereas, WSP1 and FBN2 are involved in supporting islet neogenesis. 
However, further research is required to elucidate the progenitor cells and paracrine factors 
that formulates the islet regenerative niche, to maximize the endogenous regenerative 
potential of the endocrine pancreas.                 
28 
 
1.8.2.4 Clinical Trials Using Blood Progenitor Cells to Treat Diabetic 
Patients   
In 2005 an Argentine team infused mononucleated cells derived from the human BM 
directly into the pancreas through the splenic artery to stimulate endogenous islet 
regeneration in type 2 diabetic patients.129 Eighty-four percent of the patients that received 
this transplant were weaned off hypoglycemic pharmacological agents. In another study, 
25 type 2 diabetic patients received a combination therapy of autologous stem cell infusion 
and peri-infusion of hyperbaric oxygen treatment. Compared to baseline before treatment 
metabolic variables such as: fasting glucose, HbA1c, fasting c-peptide, and the insulin 
requirement improved in these patients 12 months after treatment.130 Although these 
preliminary results are exciting, our studies show that it is only blood-derived progenitor 
cells that stimulate robust endogenous islet regeneration. Whereas, blood-derived 
mononuclear cells do not have this effect.126–128 UCB is a readily available source of blood-
derived progenitor cells, however there is not enough of these progenitor cells in UCB to 
treat a human diabetic patient. Thus, in order for stem cell infusion to be used as a curative 
and sustainable therapy for diabetic patients, progenitor cells must be expanded, and the 
mechanism by which these cells stimulate endogenous islet regeneration must be 
understood.  
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1.9 Hypothesis and Objectives  
The overall objective of my project was to characterize UCB-derived, ALDHhi HPC 
expanded in clinically applicable serum-free culture conditions. In addition, we aimed to 
determine whether these expanded HPC subsets, selected for low versus high ALDH 
activity after culture, stimulate endogenous islet regeneration after transplantation in vivo. 
We hypothesize that HPC retaining high ALDH activity during ex vivo expansion, will 
possess islet regenerative capacity, and will lead to the recovery of hyperglycemia after 
transplantation into diabetic mice. We further hypothesize that ALDHhi HPC will secrete 
developmental cytokines that stimulate β cell proliferation and islet revascularization. 
My first objective was to characterize the cell surface phenotype and hematopoietic colony 
formation of human UCB ALDHhi cells after ex vivo expansion over a 9 day time course. 
My second objective was to investigate the mechanisms by which culture-expanded 
ALDHhi HPC could stimulate islet regeneration and recovery from hyperglycemia after 
transplantation into STZ-NOD/SCID mice. 
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2.1 Introduction  
With approximately one trillion (1012) cells arising daily in the adult human BM, blood is 
one of the most highly regenerative tissues in the body. Therefore, it is a rich source of 
adult progenitor cells that can be utilized for novel cell therapies.1 Besides hematopoietic 
repopulating capacity progenitor cells derived from BM demonstrate tissue regenerative2–
5, immunomodulatory6, and angiogenic properties.7,8 Furthermore, in a seminal publication 
investigating the effect of BM cells on islet regeneration, Hess et al.,9 showed that the 
transplantation of murine BM progenitor cells reduced hyperglycemia in STZ treated 
diabetic mice by stimulating β cell proliferation and enhancing insulin production in 
recipient derived islets in situ via undetermined paracrine mechanisms. This concept 
termed “progenitor cell-stimulated islet regeneration” has become a central process for 
pancreas repair as evidence now suggest multiple progenitor subtypes induce islet 
regeneration either by stimulating β cell expansion, or neoislet formation.10–13     
Curative therapies that re-establish functional β cell mass in patients with diabetes has been 
an area of intense pre-clinical studies over the past 10 years. There are two distinct types 
of diabetes; type 1 diabetes is associated with the autoimmune destruction of insulin 
secreting β cells, while type 2 diabetes is linked to a combination of insulin resistance, β 
cell dysfunction, and ultimately β cell failure.14,15 Currently, the symptoms associated with 
the β cell dysfunction in both type 1 and type 2 diabetic patients are treated using exogenous 
insulin. Furthermore, oral hypoglycemic agents like metformin are currently used to treat 
the peripheral insulin resistance observed in type 2 diabetic patients. Since, these 
treatments do not provide the same “on-demand” glycemic control, diabetic patients have 
more extreme peaks and troughs in blood glucose levels.16 As a result, more than 90% of 
diabetic patients develop severe vascular complications, including peripheral limb 
ischemia, heart attack, and stroke.17 In patients with severe diabetes, the success of whole 
pancreas or isolated islet transplantation via the Edmonton protocol suggests that 
hyperglycemia can be controlled by the replacement of viable β cells.18 However, 
continued autoimmune destruction of donor islets, the need for lifelong 
immunosuppressant therapy, and the critical shortage of donor pancreata and islets have 
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prevented the widespread use of these procedures.19,20 Interestingly, the medalist study has 
shown that, type 1 diabetic patients with disease duration >50 years have sustained resting 
c-peptide levels, suggesting residual β cell function.17 Also, immunohistochemical analysis 
of 9 patients that died during the study revealed the presence of proliferating insulin+ cells 
in the pancreas.17 Thus, stimulating the regeneration of endogenous β cells in situ, may 
represent a feasible approach to improve endogenous insulin production in diabetic 
patients.   
In addition to BM, UCB represents a readily available source of progenitor cells. The 
widespread initiatives to HLA-phenotype and cryopreserve human UCB in North America 
and Europe, has ensured that UCB represents a sustainable source of post-natal progenitor 
cells, for cell therapy applications. In our most recent studies, we used human UCB cells 
with high aldehyde dehydrogenase activity (ALDHhi), a conserved progenitor cell function, 
to establish that ALDHhi cells stimulate endogenous islet proliferation and 
revascularization after direct iPan ransplantation into STZ-NOD/SCID mice.11 However, 
the low number of ALDHhi cells found in UCB limits the widespread application of 
transplanted UCB-derived progenitor cells to stimulate islet regeneration in human diabetic 
patients.  
To increase the number of progenitor cells available for clinical application, we expanded 
the HPC lineage of ALDHhi UCB cells under clinically applicable, serum-free conditions. 
These conditions resulted in a 15-fold increase in total cell number, and a 3-fold increase 
in the number of HPC retaining high ALDH activity. HPC that retained high ALDH 
activity (ALDHhi HPC) highly expressed primitive hematopoietic cell surface markers 
(CD34, CD133), and demonstrated hematopoietic colony forming capacity in vitro. 
Culture-expanded ALDHhi HPC transplanted STZ-NOD/SCID mice demonstrated 
improved hyperglycemia, and glucose tolerance, increased islet size, and vascularization. 
These data identify culture-expanded ALDHhi HPC as a novel cell population for clinical 
applications, and provide strong justification for the further enhancement of expansion, re-
selection, and transplantation strategies using UCB-derived HPC to tip the balance in 
favour of islet regeneration versus destruction in patients with diabetes.  
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2.2 Methods 
2.2.1 ALDHhi Progenitor Cell Isolation from Human Umbilical Cord 
Blood 
Human UCB (N=10) was obtained with informed consent following cesarian section, by 
phlebotomy of the umbilical vein, at the Victoria Hospital Birthing Centre in London. 
Within 24 hours, UCB samples were lineage depleted (Lin-, RosetteSep™ Human Cord 
Blood Progenitor Cell Enrichment Cocktail, StemCell Technologies, Vancouver, Canada) 
and the mononuclear cells (MNC) were isolated by Hypaque Ficoll centrifugation. Lin- 
depleted MNC were incubated with the AldeflourTM reagent (StemCell Technologies), and 
fluorescence activated cell sorting (FACSAria, BD Biosciences, Mississauga, ON) was 
used to isolate cells with low side scatter and high ALDH-activity.      
2.2.2 Ex vivo Expansion of UCB ALDHhi Cells 
For ex vivo HPC expansion, freshly isolated ALDHhi UCB cells were plated into 
fibronectin coated plates in X-vivo 15 media (Lonza, Basel, Switzerland) supplemented 
with-SCF, FLT-3L, and TPO-at a concentration of 10ng/mL (Invitrogen, Burlington, ON). 
UCB ALDHhi cells were cultured for 3, 6, or 9 days, with a media change every 3 days.  
2.2.3 Characterization of Cell Surface Marker Expression on Culture-
Expanded HPC 
Day 0 fresh ALDHhi UCB or day 3, 6, or 9 culture-expanded HPC were collected and 
stained with anti-human antibodies for CD3 (T cells), CD14 (monocytes), CD19 (B cells) 
(all BD Biosciences), and HPC markers CD34 (Biolegend, San Diego, CA), CD133 
(Miltenyi Biotec, Auburn, CA). Cells were co-stained with Aldeflour™ to determine 
ALDH activity, and cell viability was assessed by trypan blue viability counts and co-
staining with 7-amino-actinomycin D (BD Biosciences). Cell surface marker expression 
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was acquired using a LSRII flow cytometer at the London Regional Flow Cytometry 
Facility, and analyzed using FlowJo software.  
2.2.4 Methylcellulose Assay 
Six day culture-expanded unsorted (Bulk) HPC, ALDHhi HPC or ALDHlo HPC 
subpopulations were seeded in methylcellulose media (H4434, Stem Cell technologies) at 
cell density of 1000 in duplicate or triplicate, and the hematopoietic colonies formed were 
phenotyped by light microscopy, and enumerated after 14 days.    
2.2.5 Transplantation of Culture-Expanded HPC Subsets into STZ-
NOD/SCID Mice 
Adult (7-12 week) NOD/SCID mice (Jackson Laboratories, Bar Harbor ME) were injected 
with STZ (35mg/kg/day) for 5 days. On day 10 these mice were sub-lethally irradiated 
(300cGy) and transplanted by i.v. injection with PBS or with 5×105 Bulk HPC, 2×105 
ALDHlo HPC, or 2×105 ALDHhi HPC. Systemic blood glucose concentrations were 
monitored weekly for 42 days. Twenty-four hours prior to sacrifice, mice were injected 
with 5-ethynyl-2’-deoxyuridine (EdU, Invitrogen) to mark proliferating cells, and glucose 
tolerance tests (2 hour duration) were performed after intraperitoneal injection of 2mg/kg 
glucose. The BM, and the duodenal (pancreas head) portion of the pancreas were collected 
and analyzed for engraftment of human cells expressing human pan-leukocyte specific 
marker CD45, and human nucleated cell marker HLA-A,B,C by flow cytometry. 
Previously, it has been shown that islet neogenesis occurs in the splenic (pancreas tail) 
portion of the pancreas.21 Therefore, to characterize the islet regenerative program 
stimulated by transplanted progenitor cells, the tail of the pancreas was harvested frozen 
and sectioned at 10 µm for immunohistochemical analysis, using a cryostat such that each 
slide contained 3 sections that were 150 µM apart, belonging to one mouse, to ensure that 
the same islet was not counted twice. For all subsequent immunohistochemical staining 
procedures the appropriate controls-primary antibody only, secondary antibody only-were 
performed to control for background staining.   
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2.2.6 Islet Size, Number, and β Cell Mass Quantification 
For islet analysis each section was fixed with 10% buffered formalin for 15 minutes 
(Sigma, St. Louis, MO), washed with PBS, and blocked with peroxidase block for 5 
minutes and mouse-on-mouse reagent for an hour (Vector, Burlington, ON). Afterwards, 
sections were incubated for 5 minutes with mouse-on-mouse protein diluents (Vector). 
Sections were then incubated with mouse insulin antibody (diluted 1/1000, Sigma) for an 
hour, which was detected with a secondary peroxidase labeled rabbit anti-mouse IgG 
antibody (1 hour incubation, diluted 1/200, Vector) and ImmPACT™ DAB (Vector), then 
counterstained with hematoxylin and mounted in vectamount (Vector). Islets were detected 
using a light microscope (BX50, Olympus, Richmond Hill, ON). In each section islets with 
a circumference above 150µm in 4 randomly selected areas (1mm2) were counted, and 
analyzed using the Northern Eclipse Software. β cell mass was calculated using the 
formula: (βcell area)/(total area – β cell area) × pancreas weight.   
2.2.7 Islet Blood Vessel Density Quantification 
In order to quantify blood vessels, each of the sections were first fixed with 10% buffered 
formalin for 15 minutes (Sigma), washed with PBS, permeabilized with 1 % Trition X-100 
(Sigma) for 20 minutes, and blocked with mouse-on-mouse reagent (vector) for an hour, 
and incubated for 5 minutes with mouse-on-mouse protein diluents (Vector). Afterwards, 
sections were incubated with mouse anti-mouse insulin primary antibody (1 hour 
incubation time, diluted 1/100, Sigma), which was detected using the Texas Red-labeled 
horse anti-mouse secondary antibody (1/200, Vector). Each section was first blocked with 
rabbit blocking buffer for an hour, then co-stained with rat anti-mouse CD31 antibody (1 
hour incubation, diluted 1/200, Chemicon, Temecula, CA), which was detected using 
Fluorescein-labeled rabbit anti-rat IgG secondary antibody (30 minute incubation, diluted 
1/200, Vector).The slides were then mounted in VectaShield with DAPI (Vector). The 
fluorescence microscope (Axio Scope Z2) and the AxioVision software were used to detect 
CD31+ vessels within islets, and in extra-islet regions. In each section intra-islets blood 
vessels, extra-islet blood vessels, and DAPI stained nuclei within the islet were quantified. 
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CD31 vessels/islet cell was calculated using the formula: intra-islet CD31+ vessels/intra-
islet DAPI stained nuclei.  
2.2.8 Quantification of Proliferating Cells  
Each section was fixed with 10% buffered formalin (Sigma) for 15 minutes, washed with 
PBS for 20 minutes, permeabilized with 1 % Trition X-100 (Sigma) for 20 minutes. EdU+ 
cells were detected using the Click-iT™ EdU imaging kit (Invitrogen) as per 
manufacturer’s protocol, and co-stained for insulin as described in the islet blood density 
protocol above. The fluorescence microscope (Axio scope Z2, Germany) and the 
AxioVision software were used to detect proliferating islet cells. EdU+ cells in each islet, 
the number of islets with at least one EdU+ cell, and DAPI nuclei were then quantified. 
Percentage of EdU+ islet cells was calculated using the following formula: (EdU+ islet 
cells/intra-islet DAPI stained nuclei) × 100. Percentage of islets with at least one EdU+ cell 
was calculated using the following formula: (islets with at least 1 EdU+ islet cell/the total 
number of islets) × 100.     
2.2.9 RNA Isolation and Microarray Analyses 
mRNA was isolated from 6 day culture-expanded ALDHhi and ALDHlo HPC in triplicate 
using the mRNeasy Mini kits (Qiagen, Dusseldorf, Germany). Microarray was performed 
using human array chips (Affymetrix, Santa Carla, CA) at the London Regional Genomic 
Center. mRNA transcripts that were significantly (p<0.05) increased by 1.5-fold in  
ALDHhi HPC vs. ALDHlo HPC (p<0.05) were identified, and then filtered for documented 
angiogenic function using the Partek Genomic Suite (Partek, Inc., St. Louis, MO).  
2.2.10 Statistical Analysis 
All data was expressed as mean ± standard error of the mean (SEM). Analysis of 
significance was performed by a two-way analysis of variance (ANOVA) for the blood 
glucose curve, and by one way ANOVA, followed by Tukey’s test for all other analyses 
unless otherwise stated.  
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2.3 Results   
2.3.1 Cells Retaining High ALDH-activity and Primitive Progenitor 
Phenotype was maximized after 6 Days of Culture 
Hematopoietic progenitor enriched human UCB Lin- cells were FACS purified based on 
low side scatter and high ALDH activity (Figure 2.1A-C), 1.7 ± 0.3% of UCB Lin- cells 
demonstrated high ALDH activity (N=10). We have previously shown purified ALDHhi 
cells represent a heterogeneous progenitor cell population, primarily composed of 
primitive hematopoietic and early myeloid progenitor cells, with murine islet regenerative 
and proangiogenic potential.7,11 Specifically, ALDHhi UCB highly co-expressed the 
hematopoietic progenitor cell markers CD34 (91.6±1.8%), and CD133 (62.2±5.7%, Figure 
2.2). We typically accrue a total of 2-4×105 from a UCB sample, and the low number of 
ALDHhi cells found in UCB limits the widespread application of transplanted UCB-derived 
progenitor cells available for regenerative therapies. Therefore, we adapted clinically 
applicable conditions to expand ALDHhi UCB cells in serum free media using the 
hematopoietic growth factors: SCF, FLT-3L, TPO.22–26 Under these hematopoietic cell 
expansion conditions fresh UCB ALDHhi cells expanded by 2.3 ± 0.4-fold at day 3, 20.7± 
2.0-fold at day 6, and 53.5 ± 9.0-fold at day 9 of culture (Table 2.1, N=5-7). Furthermore, 
the frequency of HPC retaining high ALDH-activity diminished as culture time progressed 
from 28.7 ± 2.0% at day 3, versus. 14.9 ± 3.9 % day at 6, versus. 2.2 ± 0.3% at day 9, 
(Figure 2.1D-F). Interestingly, at day 6 the culture expanded HPC population demonstrated 
the highest number of total ALDHhi (3.09 ± 1.1 fold, Figure 2.1G), ALHDhi/CD34+ (2.24 
± 0.31 fold, Figure 2.1H), and ALDHhi/CD133+ (1.84 ± 0.37 fold, Figure 2.1I) primitive 
progenitor cells. Therefore, we selected 6 day culture-expanded HPC for all further 
analyses.   
49 
 
 
Figure 2.1 Isolation and expansion kinetics of human UCB ALDHhi cells.  
Representative flow cytometry plots showing the initial purification of human UCB 
ALDHhi cells. Lineage depleted UCB cells were first gated using (A) forward and side 
scatter properties. (B) DEAB-treated controls were used to establish gates for the selection 
of (C) ALDHhi cells using the AldefluorTM assay. Purified UCB ALDHhi cells represented 
1.7±0.3% of the total Lin- cell population. (D-F) Representative FACS analysis showing 
the frequency of culture-expanded HPC that retained high ALDH-activity after culture for 
3, 6, or 9. The frequency of HPC retaining high ALDH-activity was diminished as culture 
time progressed. (G-I) Total cell expansion at days 3, 6, or 9 for ALDHhi cells, 
ALDHhi/CD34+ cells, and ALDHhi/CD133+ cells compared to the number of cells of each 
subset seeded at day 0. At day 6 cultured HPC demonstrated highest expansion of ALDHhi 
cells, ALDHhi/CD34+ cells, and ALDHhi/CD133+ cells compared to 3 day or 9 day cultured 
HPC. Data represent mean ± SEM from 5-7 UCB samples (a<b, p<0.05). 
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Figure 2.2 . Fresh UCB cells with high ALDH-activity (ALDHhi UCB) co-expressed 
hematopoetic progenitor cell surface markers.  Representative flow cytometry plots 
showing the analysis of fresh ALDHhi progenitor cells isolated from Lin- UCB. 
Specifically, flow cytometry plots of (A) Isotype control (B) of primitive cell surface 
markers expressed on fresh ALDHhi UCB cells. Data represent mean ± SEM from 3 UCB 
samples.  
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Table 2.1 Total cell expansion of ALDHhi UCB cells after 3, 6, or 9 days of culture. 
 
Human ALDHhi UCB cells were cultured for 3, 6, or 9 days, and total cell number and total 
cell fold expansion was quantified at each time point, by comparing the number cells at 
each day to the number of ALDHhi cells seeded at day 0. Data represent mean ± SEM from 
5-7 UCB samples. 
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2.3.2 The Culture-Expanded ALDHhi HPC Subset Co-Expressed 
Primitive Hematopoietic Progenitor Cell Surface Markers 
After 6 days of expansion 14.9±3.9% of cells retained high ALDH activity (Figure 2.1E). 
Therefore, the 6 day culture-expanded HPC population was categorized as Bulk HPC, 
ALDHlo HPC, and ALDHhi HPC subsets based on DEAB controls (Figure 2.3A-C), and 
each population was subsequently analyzed for primitive hematopoietic cell surface 
markers. Cell surface molecules such as CD34, and CD133 are commonly used to isolate 
primitive hematopoietic cells with in vitro and in vivo repopulating function. The 
expression of these molecules diminish with maturation and differentiation.1,27,28 These cell 
surface molecules were highly expressed on freshly isolated BM, and UCB ALDHhi 
progenitor cells with islet regenerative functions (Figure 2.2).8,11,12 Compared to the Bulk 
HPC, and ALDHlo HPC, the ALDHhi HPC subset was highly enriched for primitive 
hematopoietic cell surface markers (69.3 ± 6.4% CD34+, 40.3 ± 8.1% CD133+, Table 2.2). 
In addition, the islet regenerative BM and UCB derived ALDHhi progenitor cells are 
enriched for CD34+/CD38- and CD34+/CD133+ primitive progenitor populations (Figure 
2.2).8,27 ALDHhi HPC showed a significantly higher frequency of cells expressing this 
primitive hematopoietic progenitor cell phenotype (34.8 ± 6.6% CD34+/CD38-, 41.6 ± 
7.4% CD34+/CD133+, Figure 2.2D-J) compared to Bulk HPC and ALDHlo HPC subsets. 
Notably, ALDHhi HPC did not acquire mature monocyte (0.4±0.1% CD14+, Table 2.2) or 
macrophage markers (0.8 ±0.2% CD11b+,Table 2.2). These data suggests that the 6 day 
culture-expanded ALDHhi HPC sub-population retains a primitive hematopoietic 
progenitor phenotype, without full differentiation to the monocyte or macrophage lineage.  
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Figure 2.3 Culture-expanded cells retaining high ALDH-activity (ALDHhi HPC) co-
expressed progenitor cell surface markers and demonstrated hematopoietic colony 
forming function in vitro.  Representative flow cytometry plots showing the analysis of 
expanded HPC subsets after 6 days culture. (A) DEAB controls were used to establish gates 
for (B) Bulk HPC and (C) ALDHlo versus ALDHhi HPC subsets. (D-I) Representative flow 
cytometry plots of primitive cell surface markers expressed on expanded HPC subsets. (J) 
ALDHhi HPC showed significantly higher frequency of cells expressing a primitive HPC 
phenotype (CD34+/CD38-, CD34+/CD133+). (K-L) Bulk HPC, ALDHlo HPC, or ALDHhi 
HPC were cultured in MethylcelluloseTM media and colonies of erythrocyte, granulocyte, 
and macrophage lineages were enumerated after 14 days. ALDHhi HPC were enriched for 
total hematopoietic colony forming cells, and ALDHhi HPC formed significantly more 
erythroblast, and granulocyte colonies compared to ALDHlo HPC. Data represent mean ± 
SEM from 5-6 UCB samples (a<b<c, p<0.05). 
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Table 2.2 Analyses of Bulk HPC, ALDHlo HPC, and ALDHhi HPC for expression of 
hematopoietic cell surface markers. 
 
ALDHhi HPC demonstrated increased levels of primitive cell surface markers (CD34 and 
CD133) compared to Bulk HPC and ALDHlo HPC. Data represent mean ± SEM from 4-6 
UCB samples (a<b, p<0.05). 
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2.3.3 The Culture-Expanded ALDHhi HPC Subset Contained 
Multipotent Hematopoietic Colony Forming Cells 
In order to determine whether ALDHhi HPC retained hematopoietic colony forming cell 
activity after 6 days of expansion, Bulk HPC or ALDHlo HPC or ALDHhi HPC were plated 
in methylcellulose media, and the clonogenic hematopoietic colonies formed were 
enumerated after 14 days. Compared to ALDHlo HPC, the ALDHhi HPC subset was 
enriched for total multipotent hematopoietic colony cells (9.6 ± 0.7% ALDHhi HPC versus. 
6.1 ± 1.7 ALDHlo HPC, Figure 2.3K). Particularly, ALDHhi HPC formed significantly 
more erythroblast, and granulocyte colonies compared to ALDHlo HPC (Figure 2.3L). 
Therefore, the ALDHhi HPC subset retained a greater hematopoietic colony forming 
capacity compared to the ALDHlo HPC subset.      
2.3.4 Transplantation of Culture-Expanded ALDHhi HPC Improved 
Islet function.   
Our  group has previously found that the transplantation ALDHhi UCB improved the islet 
function of STZ-NOD/SCID diabetic mice.11 However, the low number of ALDHhi cells 
found in UCB limits the widespread application of transplanted UCB-derived progenitor 
cells to treat diabetes. Therefore, our goal was to expand ALDHhi UCB cells, in 
hematopoietic culture, while retaining its islet regenerative functions. To investigate the 
islet regenerative capacity of fresh ALDHhi UCB-derived, culture-expanded HPC 
populations in vivo, STZ-treated NOD/SCID mice were i.v. injected with PBS or 5×105 
Bulk HPC on day 10, and blood glucose levels were assessed until day 42 (Figure 2.4A). 
Similar to PBS-injected controls, mice i.v. transplanted with Bulk HPC remained severely 
hyperglycemic (>25mmol/L,Figure 2.4B), suggesting a loss of islet regenerative function 
in the Bulk HPC population, as a result of 6 day ex vivo expansion. Therefore, the Bulk 
HPC were re-selected after culture expansion by FACS for the sub-populations with low 
(ALDHlo HPC) versus high ALDH (ALDHhi HPC) activity (as seen in figure 2.3C). After 
i.v. transplantation of 2×105 cells, mice transplanted with ALDHlo HPC remained severely 
hyperglycemic (>25mmol/L,Figure 2.4B). Remarkably, mice transplanted with an equal 
dose ALDHhi HPC demonstrated reduced systemic glucose levels from day 17-42  
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Figure 2.4 Transplantation of culture-expanded ALDHhi HPC improved 
hyperglycemia and glucose tolerance in STZ-NOD/SCID mice. (A) STZ-NOD/SCID 
mice (35mg/kg/day, days 1-5) were sublethally irradiated and i.v. injected with PBS (blue, 
n=8 mice); 5x105 Bulk HPC (orange, n=9 mice), 2x105 ALDHlo HPC (red, n=9 mice), or 
2x105 ALDHhi HPC (green, n=9 mice) on day 10 and blood glucose levels were monitored 
for 42 days. (B) Compared to mice transplanted with PBS, Bulk HPC or ALDHlo HPC, 
mice transplanted with ALDHhi HPC showed reduced resting blood glucose levels from 
days 17-42, and (C) reduced area under the curve. (D) At day 41 a glucose tolerance test 
was performed on mice transplanted with PBS (n=3) ALDHlo HPC (n=9) and ALDHhi HPC 
(n=9). Compared to PBS-injected or ALDHlo HPC, mice transplanted with ALDHhi HPC 
showed improved glucose tolerance, and (E) reduced area under the curve. Data represent 
mean ± SEM from 5-7 UCB samples (a<b, p<0.05; *p<0.05).  
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compared to mice from all other treatment groups (Figure 2.4B). After performing area 
under the curve (AUC) analyses on all i.v.-transplanted mice, ALDHhi HPC transplanted 
mice showed significantly reduced hyperglycemia compared to all other treatment groups 
(Figure 2.4C).  Furthermore, compared to mice transplanted with PBS or ALDHlo HPC, 
mice transplanted with the culture-expanded ALDHhi HPC subset showed improved 
glucose tolerance (Figure 2.4D-E). This suggests that the i.v. transplantation of ALDHhi 
HPC subset improved the glucose response in STZ-NOD/SICD mice. 
2.3.5 Culture-Expanded ALDHhi HPC Engrafted in the Murine BM 
To correlate the improvement of glycemic control with human cell engraftment the BM 
and the head of the pancreas was collected at day 42, and analyzed for the presence of 
human CD45+ and HLA-ABC by flow cytometry. Only the culture-expanded ALDHhi 
HPC subset consistently engrafted in the murine BM, however human cells were not 
detected in the murine pancreas by flow cytometry at day 42 (Figure 2.5A-C). Although, 
analysis at earlier time points is required to delineate the recruitment kinetics of ALDHhi 
HPC to the injured pancreas of STZ-NOD/SCID mice after i.v. injection, our previous 
studies with freshly isolated ALDHhi UCB cells have documented low level pancreas 
engraftment at 7 day post-transplantation.12     
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Figure 2.5 Engraftment of human UCB-derived ALDHhi progenitor cells in the BM 
and pancreas of STZ-NOD/SCID mice.  (A) Representative flow cytometry plots of 
human cell engraftment at day 42 in the BM and pancreas of recipient mice i.v. transplanted 
with Bulk HPC (n=9), ALDHlo HPC (n=9), or ALDHhi HPC (n=9). (B) Transplantation of 
ALDHhi cells, but not Bulk HPC or ALDHlo HPC, resulted in consistent human 
hematopoietic chimerism in mouse BM. (C) Bulk HPC, ALDHlo HPC or ALDHhi HPC 
were not detected in the mouse pancreas at day 42. Data Represents Mean ± SEM from 5-
7 UCB samples.    
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2.3.6 Transplantation of Culture-Expanded ALDHhi HPC Increased 
Islet Size, and β Cell Mass   
To determine the mechanisms by which ALDHhi HPC improved glycemic control, 
pancreas sections of transplanted mice were stained for murine insulin (Figure 2.6A-D), 
and analyzed for islet size (Figure 2.6E), islet number (Figure 2.6F), and total β cell mass 
(Figure 2.6G). Mice transplanted with Bulk HPC, and ALDHlo HPC had a similar islet size, 
islet number and β cell mass as PBS injected controls. In contrast, ALDHhi HPC 
transplanted mice showed a significant (p<0.05) increase in islet size (circumference), and 
β cell mass, but not islet number compared to mice from all other treatment groups. All 
islets were derived from murine cells suggesting that transplantation ALDHhi HPC 
improves islet function by stimulating an endogenous islet regeneration. 
2.3.7 Transplantation of Culture-Expanded ALDHhi HPC Increased 
Islet Vascularization 
We postulated that improved hyperglycemia (Figure 2.4) and increased islet size (Figure 
2.6E) after culture-expanded ALDHhi HPC transplantation may also correlate with 
progenitor-stimulated islet vascularization.7,11,12 Thus, mouse pancreas sections were 
stained with murine insulin and CD31-a marker of endothelial cells within blood vessels 
at day 42 (Figure 2.7 A-F). The intra-islet and extra-islet microvessel densities in mice 
transplanted with Bulk HPC and ALDHlo HPC were similar to PBS injected mice (Figure 
2.7A-C). Interestingly, mice transplanted with ALDHhi HPC showed augmented islet 
vascularization with increased numbers of CD31+ cells (Figure 2.7D, arrowheads). 
Furthermore, higher zoom of the representative inset shows CD31 expressing cells in close 
association with insulin+ β cells within the regenerating islet (Figure 2.7E), and CD31+ 
cells were distinct and formed continuous vessels (Figure 2.7F, arrows). 
Histomorphometric quantification of intra-islet capillary density was significantly 
increased (p<0.05) in ALDHhi HPC transplanted mice, compared to all other treatment 
groups (Figure 2.7F). Interestingly, similar analyses quantifying extra-islet vascularization 
were equivalent (Figure 2.7H), when compared to mice from all other treatment groups.  
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Figure 2.6 Transplantation of culture-expanded ALDHhi HPC increased islet size and 
β cell mass without increasing total islet number.  Representative photomicrographs of 
islet structures (brown) at day 42 in STZ-NOD/SCID mice i.v. injected with (A) PBS (n=6), 
(B) Bulk HPC (n=9), (C) ALDHlo HPC (n=5), or (D) ALDHhi HPC (n=6). Compared to 
PBS controls, or mice transplanted with Bulk HPC or ALDHlo HPC, mice transplanted 
with ALDHhi HPC showed (E) significantly increased islet circumference, (F) equivalent 
islet number, (G) and increased β cell mass. Data represent mean ± SEM from 3-6 UCB 
samples (a<b, p<0.05). 
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Figure 2.7 Transplantation of culture-expanded ALDHhi HPC increased islet 
vascularization. Representative photomicrographs of CD31+ blood vessels (green) 
associated with insulin+ islets (red) at day 42 in STZ-NOD/SCID mice transplanted with 
(A) PBS (n=7), (B) Bulk HPC (n=9), (C) ALDHlo HPC (n=5), or (D) ALDHhi HPC 
(n=8). Arrowheads mark CD31+ cells within islets. (E) Higher zoom of the inset shown in 
(D) clearly shows CD31+ cells in close association with insulin expressing β cells within 
regenerating islets. (F) Transplantation of UCB ALDHhi HPC also induced the appearance 
of CD31+ vessel structures within and immediately surrounding insulin+ islets. Arrows 
mark CD31+ continuous vessels. (G) Compared to mice transplanted with PBS, Bulk HPC, 
and ALDHlo HPC, mice transplanted with ALDHhi HPC showed increased vascularization 
within islets, but not in (H) extra-islet areas. Data represents mean ± SEM from N=3-6 
UCB samples (a<b, p<0.05).  
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These data suggest that transplantation of ALDHhi HPC stimulated islet-specific 
revascularization. 
2.3.8 Mice Transplanted with Culture-Expanded ALDHhi HPC 
Demonstrated an Increase in Proliferating Islets   
To further investigate an increase in islet size, EdU incorporation into proliferating islets 
were analyzed at day 42 (Figure 2.8A-D). According to a student’s t-test, compared to mice 
transplanted with PBS, ALDHhi HPC transplanted mice demonstrated a significantly 
higher % EdU+ islet cells (Figure 2.8E), and a significant increase (p<0.05) in the % islets 
with at least one EdU+ proliferating cell (Figure 2.8F). Our previous studies with freshly 
isolated ALDHhi cells have documented augmented islet proliferation at 7 day post-
transplantation.12    Although analyses of islet proliferation at earlier time points were not 
performed, these data suggest that transplantation of culture-expanded ALDHhi HPC 
stimulated islet proliferation.   
2.3.9 Culture-Expanded ALDHhi HPC Demonstrated a Pro-angiogenic 
Transcription Profile  
Affymetrix microarray analyses were performed on three ALDHhi HPC samples compared 
to sample matched ALDHlo HPC, and 406 transcripts with significantly (p<0.05) increased 
expression were identified. These samples were filtered for documented angiogenic 
biological function. As an internal control for the selection of HPC with high ALDH 
activity, ALDHA1 mRNA expression was higher by 3.7-fold in ALDHhi HPC versus 
ALDHlo HPC (Table 2.2). Furthermore significantly higher CD34, PROM1 (Table 2.3) 
mRNA expression in ALDHhi HPC correlated with increased CD34, and CD133 cell-
surface protein expression, previously observed by flow cytometry (Table 2.2). 
Interestingly, transcripts associated with vascular cell signaling, and angiogenic cytokines 
were increased in ALDHhi HPC, compared to the ALDHlo HPC subset (Table 2.4).  
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Figure 2.8 Transplantation of culture-expanded ALDHhi HPC increased proliferating 
Islets. Representative photomicrographs of EdU+ proliferating cells (green) within insulin+ 
islets (red) at day 42. STZ-NOD/SCID mice transplanted with (A) PBS (n=4), (B) Bulk 
HPC (n=7), (C) ALDHlo HPC (n=4), or (D) ALDHhi HPC (n=7). Arrowheads mark 
EdU+ proliferating cells within islets. (E) Compared to mice transplanted with PBS mice 
transplanted with ALDHhi HPC showed an increase in percentage of EdU+ cells within 
islets and, (F) an increase in the percentage of islets with at least one EdU+ proliferating 
cell. Data represent mean ± SEM from 3-5 UCB samples (*p<0.05). 
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Table 2.3 . Progenitor cell-associated transcripts encoding progenitor cell markers, 
with increased expression in ALDHhi HPC versus ALDHlo HPC 
 
FC Fold change MAPK mitogen-activated protein kinase CD cluster of differentiation. 
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Table 2.4 Angiogenesis-associated transcripts encoding secreted proteins, and cell 
surface proteins with increased expression in ALDHhi HPC versus ALDHlo HPC 
 
FC Fold change EGF epidermal growth factor TIMP tissue inhibitors of 
metalloaproteinases ETS E26 transformation-specific 
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2.4 Discussion 
These studies demonstrated that the HPC lineage of fresh ALDHhi UCB cells expands 
efficiently in culture, and that only the HPC sub-population that retains high ALDH activity 
stimulates islet regeneration when i.v.-transplanted into STZ-NOD/SCID mice. UCB 
ALDHhi cells expanded in serum-free media supplemented with hematopoietic cytokines 
SCF, TPO, and FLT-3L. Although, the highest number of total HPC was observed after 9 
days of ex vivo expansion, the highest number of ALDHhi HPC was observed after 6 days 
of ex vivo expansion. Interestingly, the culture-expanded ALDHhi HPC subset 
demonstrated primitive hematopoietic progenitor cell phenotype, and multipotent colony 
formation. In addition, the ALDHhi HPC subset highly expressed pro-angiogenic 
transcripts. Transplantation of 6 day culture-expanded ALDHhi HPC also improved islet 
function, increased β cell mass, and augmented islet vascularization in STZ-NOD/SCID 
mice. Collectively, these data suggest that culture-expanded ALDHhi HPC from human 
UCB represent a readily available, and novel population for the development of cellular 
therapies to promote endogenous islet regeneration.   
UCB ALDHhi progenitor cells were highly proliferative in culture. We achieved a total cell 
expansion of 2.3-fold, 20.7-fold, and 53.5-fold after 3, 6, and 9 days of culture, 
respectively. Studies have shown that culturing UCB-derived progenitor cells with 
hematopoietic cytokines results in a significant expansion of committed progenitor cells, 
with only a minimal expansion of primitive progenitor cells.25 We used relative ALDH 
activity after culture to distinguish primitive hematopoietic progenitor cells (ALDHhi 
HPC), from culture differentiated, more committed progenitor cells (ALDHlo HPC). 
Compared to ALDHlo HPC, ALDHhi HPC demonstrated increased expression of primitive 
cell surface markers, and were enriched for multipotent colony forming cells in vitro. 
Similar to previous studies25,26,29,30, we found that the frequency of primitive progenitor 
cells (ALDHhi HPC) declined as culture progressed. Furthermore, committed progenitor 
cells in culture have been shown to secrete factors such as TGFβ that limit the proliferation 
of primitive progenitor cells.31–36 Due to the accumulation of inhibitory soluble factors in 
primary HPC cultures, we wanted to determine the time point that yielded the highest 
number of primitive ALDHhi HPC. These analyses revealed that 6 days of ex vivo 
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expansion, yielded the highest number of ALDHhi, ALDHhi/CD34+ HPC, and 
ALDHhi/CD133+ HPC, with a drastic decrease in HPC with these primitive phenotypes at 
day 9. Thus, we characterized the islet regenerative properties using day 6 culture-
expanded HPC subpopulations purified using low versus high ALDH activity.  
The endocrine pancreas is a highly vascularized tissue, it has 5-7 times more capillaries 
than the surrounding exocrine pancreas tissue.37 A dense capillary network is required for 
β cell to optimally sense blood glucose levels, and the fenestrations in the islet capillary 
endothelium is the most efficient way for insulin to be secreted by β cells into the systemic 
circulation.38 Thus, the islet capillary network is essential for optimal islet function. 
Furthermore, hepatocyte growth factor (HFG) secreted by endothelial cells, and laminin 
which is presented on the basement membrane of the islet capillary network have been 
shown to stimulate β cell proliferation.39,40 Collectively, these studies suggest that 
endothelial-endocrine axis plays an important role in supporting β cell function, and β cell 
turnover. Previously, we have shown that freshly isolated ALDHhi UCB cells contains pro-
angiogenic progenitor cells that improve perfusion after transplantation into mice with 
hind-limb ischemia.7 Here we show that culture-expanded ALDHhi HPC, derived from 
freshly isolated UCB cells with high ALDH activity, enhanced islet-specific 
vascularization in the STZ-NOD/SICD mouse pancreas. Increased vascularization was 
specific to the islets, rather than extra-islet pancreatic tissue, suggesting that culture-
expanded ALDHhi HPC stimulates an islet specific vascularization program after 
transplantation into STZ-NOD/SCID mice. Interestingly, an increased vascularization was 
associated with an increased islet size, β cell mass, and an improved islet function. 
Collectively, our data suggest that ALDHhi HPC improves islet function in STZ-
NOD/SCID mice, by re-establishing the endothelial-endocrine axis. 
This study also begins to address the transcriptional, and secretory activities of 6 day 
culture-expanded ALDHhi HPC. The transcripts of the secreted proteins Semaphorin 4A 
(SEMA4A), Angiopoietin 2 (ANGPT2), and Milk Fat Globule-EGF factor 8 (MFG-E8) 
were higher in culture-expanded ALDHhi HPC compared to ALDHlo HPC. The proteins 
encoded by these transcripts are all involved in supporting vascular endothelial growth 
factor-A (VEGFA) mediated angiogenesis. MFG-E8 also known as lactadherin has been 
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shown to interact with αvβ3 integrins on endothelial cells, and has been shown to be critical 
in VEGFA induced angiogenesis.41 In the hind-limb ischemic model, injection of anti-
MFG-E8 blocked VEGFA induced angiogenesis.41 The transcript of ANGPT2 was also 
higher in culture-expanded ALDHhi HPC. Studies have shown that, ANGPT2 is a complex 
regulator of vascular remodelling that plays a role in both vessel sprouting, and vessel 
regression. Studies have suggested that ANGPT2 in the presence of VEGF stimulates 
vessel sprouting.42–47 Pancreatic β cells express high levels of VEGF.38,48,49 It is plausible 
that MFG-E8, and ANGPT2 secreted by ALDHhi HPC stimulate islet vascularization, by 
supporting a VEGF dependent angiogenic program.  
Finally, the transcript of SEMA4A was higher in culture-expanded ALDHhi HPC. 
SEMA4A has been shown to act on PlexinD1 receptors on macrophages, to stimulate the 
release of VEGFA from macrophages.50 The VEGFA subsequently secreted from 
macrophages, after SEM4A stimulation exerted a pro-angiogenic effect on endothelial 
cells in vitro, and in vivo. Mouse macrophages are recruited to pancreas during injury.51 
SEM4A produced by ALDHhi cells may act on the PlexinD1 receptors on these mouse 
macrophages to stimulate VEGFA release, which subsequently supports angiogenesis in 
the pancreas of STZ-diabetic mice. Collectively, these data suggest that a pro-angiogenic 
microenvironment may be established in the pancreas of STZ-NOD/SCID diabetic mice, 
after the transplantation of ALDHhi HPC.      
Intra-pancreatic transplantation of freshly isolated UCB cells with high ALDH activity 
stimulated islet revascularization, and β cell proliferation in STZ-NOD/SCID diabetic 
mice, despite the low level of engraftment of UCB ALDHhi cells in the pancreas (0.09 ± 
0.03%, n=6 mice), at day 42.11 The freshly isolated ALDHhi UCB cells created a 
regenerative niche around the islets 7 days after transplantation, and initiated a regenerative 
process. Pancreatic β cells, and ductal cells secrete cytokines, and chemokines after damage 
that recruit angiogenic cells to the pancreas. However, in this study human cells were not 
detected in the murine pancreas, at day 42, after i.v. transplantation of culture-expanded 
ALDHhi HPC. It is possible that i.v.-injected culture-expanded ALDHhi HPC are recruited 
to the damaged islets at early time points, surround these damaged islets and secrete factors 
that stimulate islet regeneration. Due to the unfavourable environment of the pancreas, 
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culture-expanded ALDHhi HPC may undergo apoptosis, or migrate away from the pancreas 
before day 42. IPan transplantation of culture-expanded ALDHhi HPC may further increase 
pancreas engraftment, and the islet regenerative response even though ALDHhi HPC may 
not survive, or migrate away from the pancreas after regenerative programs are initiated.  
This study shows that it is only primitive ALDHhi HPC that stimulates endogenous islet 
regeneration. Currently, researchers are attempting to develop protocols aimed at 
efficiently expanding primitive HPC, and limiting unwanted cellular differentiation during 
ex vivo expansion.22,52–55 For instance, Boitano et al56 have found that StemRegenin1 
(SR1)-an aryl hydrocardon receptor antagonist-promotes the expansion of human 
hematopoietic stem and progenitor cells. When added to serum free media supplemented 
with hematopoietic growth factors this compound increased the number of primitive 
CD34+ cells by 73-fold, when compared to cells cultured with only growth factors. In 
addition, the expanded CD34+ cells retain both their multilineage, and long-term 
engraftment potential. Hence, small molecules such as SR1 may be used in future 
experiments to increase the number of HPC available for the treatment of diabetic patients.       
In Summary, these studies provide proof-of-concept that ALDHhi UCB cells can be 
expanded under clinically applicable hematopoietic culture conditions, and it is only the 
culture-expanded primitive progenitor population (ALDHhi HPC) that retains islet 
regenerative function, after transplantation in vivo. Thus, optimization of ex vivo expansion 
strategies, and reselection of primitive cells using ALDH activity, may potentially lead to 
the development of a cell based therapy to treat diabetes using culture-expanded allogeneic 
UCB. Further elucidation of the mechanism by which progenitor cells stimulate islet 
regeneration is also required to maximize islet regenerative therapies to treat diabetic 
patients.    
 
 
70 
 
2.5 References 
1. Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: a human perspective. 
Cell Stem Cell. 2012;10(2):120–36.  
2. Ciceri F, Piemonti L. Bone marrow and pancreatic islets: an old story with new 
perspectives. Cell Transplant. 2010;19(12):1511–22.  
3. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow stem cells regenerate infarcted 
myocardium. Pediatr. Transplant. 2003;7 Suppl 3(April):86–8.  
4. Balsam LB, Wagers AJ, Christensen JL. Haematopoietic stem cells adopt mature 
haematopoietic fates in ischaemic myocardium. Nature. 2004;428(8):668–673.  
5. QUAINI F, URBANEK K, BELTRAMI A, et al. CHIMERISM OF THE 
TRANSPLANTED HEART. N. Engl. J. Med. 2002;346(1):5–15.  
6. Zhao Y, Jiang Z, Zhao T, et al. Reversal of type 1 diabetes via islet β cell 
regeneration following immune modulation by cord blood-derived multipotent 
stem cells. BMC Med. 2012;10(1):3.  
7. Putman DM, Liu KY, Broughton HC, Bell GI, Hess D a. Umbilical cord blood-
derived aldehyde dehydrogenase-expressing progenitor cells promote recovery 
from acute ischemic injury. Stem Cells. 2012;30(10):2248–60.  
8. Capoccia BJ, Robson DL, Levac KD, et al. Revascularization of ischemic limbs 
after transplantation of human bone marrow cells with high aldehyde 
dehydrogenase activity. Blood. 2009;113(21):5340–51.  
9. Hess D, Li L, Martin M, et al. Bone marrow-derived stem cells initiate pancreatic 
regeneration. Nat. Biotechnol. 2003;21(7):763–70.  
10. Bell GI, Meschino MT, Hughes-Large JM, et al. Combinatorial human progenitor 
cell transplantation optimizes islet regeneration through secretion of paracrine 
factors. Stem Cells Dev. 2012;21(11):1863–76.  
11. Bell GI, Putman DM, Hughes-Large JM, Hess D a. Intrapancreatic delivery of 
human umbilical cord blood aldehyde dehydrogenase-producing cells promotes 
islet regeneration. Diabetologia. 2012;55(6):1755–60.  
12. Bell GI, Broughton HC, Levac KD, et al. Transplanted human bone marrow 
progenitor subtypes stimulate endogenous islet regeneration and revascularization. 
Stem Cells Dev. 2012;21(1):97–109.  
71 
 
13. Lee RH, Seo MJ, Reger RL, et al. Multipotent stromal cells from human marrow 
home to and promote repair of pancreatic islets and renal glomeruli in diabetic 
NOD/scid mice. Proc. Natl. Acad. Sci. U. S. A. 2006;103(46):17438–43.  
14. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and 
diabetes-related complications. Phys. Ther. 2008;88(11):1254–64.  
15. Poitout V, Robertson RP. AN INTEGRATED VIEW OF β -CELL 
DYSFUNCTION IN TYPE-II. Annu. Rev. Med. 1996;47:69–83.  
16. Aguayo-Mazzucato C, Bonner-Weir S. Stem cell therapy for type 1 diabetes 
mellitus. Nat. Rev. Endocrinol. 2010;6(3):139–48.  
17. Keenan HA, Sun JK, Levine J, et al. Residual Insulin Production and Pancreatic 
Beta-Cell Turnover After 50 Years of Diabetes : Joslin Medalist Study. Diabetes. 
2010;59(11):2846–2853.  
18. Bonner-Weir S, Weir GC. New sources of pancreatic beta-cells. Nat. Biotechnol. 
2005;23(7):857–61.  
19. Ludwig B, Ludwig S, Steffen A, Saeger H-D, Bornstein SR. Islet versus pancreas 
transplantation in type 1 diabetes: competitive or complementary? Curr. Diab. 
Rep. 2010;10(6):506–11.  
20. Ryan E a, Paty BW, Senior P a, et al. Five-year follow-up after clinical islet 
transplantation. Diabetes. 2005;54(7):2060–9.  
21. Wang RN, Kliippel G, Bouwens L, Jette C. Duct- to islet-cell differentiation and 
islet growth in the pancreas of duct-ligated adult rats. Diabetelogia. 
1995;38(12):1405–1411.  
22. Csaszar E, Kirouac DC, Yu M, et al. Rapid expansion of human hematopoietic 
stem cells by automated control of inhibitory feedback signaling. Cell Stem Cell. 
2012;10(2):218–29.  
23. Ghiaur G, Yegnasubramanian S, Perkins B, et al. Regulation of human 
hematopoietic stem cell self-renewal by the microenvironment’s control of retinoic 
acid signaling. Proc. Natl. Acad. Sci. U. S. A. 2013;110(40):16121–6.  
24. Chute JP, Muramoto GG, Whitesides J, et al. Inhibition of aldehyde 
dehydrogenase and retinoid signaling induces the expansion of human 
hematopoietic stem cells. Proc. Natl. Acad. Sci. U. S. A. 2006;103(31):11707–12.  
25. Bhatia M, Bonnet D, Kapp U, et al. Quantitative Analysis Reveals Expansion of 
Human. J. Exp. Med. 1997;186(4):619–624.  
72 
 
26. Flores-Guzmán P, Fernández-Sánchez V, Mayani H. Concise review: ex vivo 
expansion of cord blood-derived hematopoietic stem and progenitor cells: basic 
principles, experimental approaches, and impact in regenerative medicine. Stem 
Cells Transl. Med. 2013;2(11):830–8.  
27. Hess D a, Meyerrose TE, Wirthlin L, et al. Functional characterization of highly 
purified human hematopoietic repopulating cells isolated according to aldehyde 
dehydrogenase activity. Blood. 2004;104(6):1648–55.  
28. Civin CI, Loken MR. Concise Review. Int. J. Cell Cloning. 1987;5(4):267–288.  
29. Fernández-Sánchez V, Pelayo R, Flores-Guzmán P, et al. In vitro effects of 
stromal cells expressing different levels of Jagged-1 and Delta-1 on the growth of 
primitive and intermediate CD34(+) cell subsets from human cord blood. Blood 
Cells. Mol. Dis. 2011;47(4):205–13.  
30. Dahlberg A, Delaney C, Bernstein ID. Ex vivo expansion of human hematopoietic 
stem and progenitor cells. Blood. 2011;117(23):6083–90.  
31. Kirouac DC, Madlambayan GJ, Yu M, et al. Cell-cell interaction networks 
regulate blood stem and progenitor cell fate. Mol. Syst. Biol. 2009;5(293):293.  
32. Csaszar E, Chen K, Caldwell J, Chan W, Zandstra PW. Real-time monitoring and 
control of soluble signaling factors enables enhanced progenitor cell outputs from 
human cord blood stem cell cultures. Biotechnol. Bioeng. 2013;9999:1–7.  
33. Van Ranst P, Snoeck H, Lardon F, et al. TGF-beta and MIP-1 alpha exert their 
main inhibitory activity on very primitive CD34+2CD38- cells but show opposite 
effects on more mature CD34+CD38+ human hematopoietic progenitors. Exp. 
Hematol. 1996;24(13):1509–1515.  
34. Sansilvestri P, Cardoso AA, Batard P, et al. Early CD34high Cells Can Be 
Separated Into KIThigh Cells in Which Transforming Growth Factor-Beta (TGF-
Beta) Downmodulates c-kit and KITlow Cells in Which Anti-TGF-Beta 
Upmodulates c-kit. Blood. 1995;86(5):1729–1735.  
35. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor- β: pleiotropic 
role in the regulation of hematopoiesis. Blood. 2000;96(6):2022–2036.  
36. Ramsfjell V, Borge OJ, Cui L, Jacobsen SEW. Thrombopoietin Directly and 
Potently Stimulates Multilineage Growth and Progenitor Cell Expansion from 
Primitive (CD34+CD38-) Human Bone Marrow Progenitor Cells. J. Immunol. 
1997;158(11):5169–5177.  
37. Nikolova G, Strilic B, Lammert E. The vascular niche and its basement membrane. 
Trends Cell Biol. 2007;17(1):19–25.  
73 
 
38. Lammert E, Gu G, Mclaughlin M, et al. Role of VEGF-A in Vascularization of 
Pancreatic Islets. Curr. Biol. 2003;13(12):1070–1074.  
39. Johansson M, Mattsson G, Andersson A, Jansson L, Carlsson P-O. Islet 
endothelial cells and pancreatic beta-cell proliferation: studies in vitro and during 
pregnancy in adult rats. Endocrinology. 2006;147(5):2315–24.  
40. Nikolova G, Jabs N, Konstantinova I, et al. The vascular basement membrane: a 
niche for insulin gene expression and Beta cell proliferation. Dev. Cell. 
2006;10(3):397–405.  
41. Silvestre J-S, Théry C, Hamard G, et al. Lactadherin promotes VEGF-dependent 
neovascularization. Nat. Med. 2005;11(5):499–506.  
42. Goede V, Schmidt T, Kimmina S, Kozian D, Augustin H. Analysis of blood vessel 
maturation processes during cyclic ovarian angiogenesis. Lab Investig. 
1998;78(11):1385–1394.  
43. Holash J, Maisonpierre P, Compton D, et al. Vessel Cooption, Regression, and 
Growth in Tumors Mediated by Angiopoietins and VEGF. Science. 
1999;284(5422):1994–1998.  
44. Maisonpierre PC. Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in 
vivo Angiogenesis. Science. 1997;277(5322):55–60.  
45. Stratmann a, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 
and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am. J. Pathol. 
1998;153(5):1459–66.  
46. Zagzag D, Hooper a, Friedlander DR, et al. In situ expression of angiopoietins in 
astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. 
Exp. Neurol. 1999;159(2):391–400.  
47. Wigle JT, Oliver G. Prox1 function is required for the development of the murine 
lymphatic system. Cell. 1999;98(6):769–78.  
48. Inoue M, Hager JH, Ferrara N, Gerber H-P, Hanahan D. VEGF-A has a critical, 
nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. 
Cancer Cell. 2002;1(2):193–202.  
49. Lecouter J, Kowalski J, Foster J, et al. Identification of an angiogenic mitogen 
selective for endocrine gland endothelium. Nature. 2001;412(6850):877–884.  
50. Meda C, Molla F, De Pizzol M, et al. Semaphorin 4A exerts a proangiogenic effect 
by enhancing vascular endothelial growth factor-A expression in macrophages. J. 
Immunol. 2012;188(8):4081–92.  
74 
 
51. Parsa R, Andresen P, Gillett A, et al. Adoptive transfer of immunomodulatory M2 
macrophages prevents type 1 diabetes in NOD mice. Diabetes. 2012;61(11):2881–
92.  
52. McNiece I, Harrington J, Turney J, Kellner J, Shpall EJ. Ex vivo expansion of cord 
blood mononuclear cells on mesenchymal stem cells. Cytotherapy. 2004;6(4):311–
7.  
53. Peled T, Landau E, Prus E, Treves AJ. Cellular copper content modulates 
differentiation and self-renewal in cultures of cord blood-derived CD34 + cells. Br. 
J. Haematol. 2002;16(3):655–661.  
54. Rosler E, Brandt J, Chute J, Hoffman R. Cocultivation of umbilical cord blood 
cells with endothelial cells leads to extensive amplification of competent CD34+ 
CD38- cells. Exp. Hematol. 2000;28(7):841–852.  
55. Delaney C, Heimfeld S, Brashem-Stein C, et al. Notch-mediated expansion of 
human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat. 
Med. 2010;16(2):232–6.  
56. Boitano AE, Wang J, Romeo R, et al. Aryl Hydrocarbon Receptor Antagonist 
Promotes the Expansion of Human Hematopoietic Stem Cells. Science (80 ). 
2011;329(5997):1345–1348.  
 
 
 
 
 
 
 
 
 
 
75 
 
 
 
 
 
 
 
 Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
3.1 Summary 
The primary objective of this research, was to determine whether expanded UCB ALDHhi 
cells could stimulate endogenous islet regeneration after transplantation into STZ-
NOD/SCID mice. UCB ALDHhi cells were cultured for 6 days under hematopoietic serum-
free culture conditions containing the obligate growth factors, SCF, TPO, and FLT-3L. 
Maximal total cell expansion (53.5 ± 9.0-fold) was observed after 9 days of ex vivo culture, 
however, as culture time proceeded the frequency of cells retaining high ALDH activity 
and primitive cell surface phenotype (CD34, CD133) was diminished. Thus, the highest 
total number of ALDHhi HPC was observed after 6 days of ex vivo expansion, resulting in 
a 3.09 ± 1.1-fold expansion of total ALDHhi cells. Due to these consistent expansion 
kinetics, the total HPC population was categorized into Bulk HPC, ALDHlo HPC, and 
ALDHhi HPC subsets. The ALDHhi HPC subset was highly enriched for primitive 
progenitor cell surface marker expression (CD34+/CD38-, CD34+/CD133+), and retained 
multipotent colony forming capacity in clonal methylcellulose colony forming assays in 
vitro. Thus, we characterized the islet regenerative properties using day 6 culture-expanded 
HPC subpopulations purified using low versus high ALDH activity.   
We have previously shown that freshly isolated UCB-derived ALDHhi cells could reduce 
hyperglycemia after transplantation into STZ-NOD/SCID mice.1 In order to address 
whether culture-expanded HPC, derived from ALDHhi UCB cells retained the capacity to 
reduced hyperglycemia, STZ-NOD/SCID hyperglycemic mice were transplanted with 
Bulk, ALDHlo or ALDHhi HPC. Mice transplanted with culture-expanded Bulk HPC or 
ALDHlo HPC remained severely hyperglycemic. Interestingly, transplantation of ALDHhi 
HPC consistently reduced hyperglycemia via increased islet size, and islet vascularization 
upon post-mortem histochemical analyses. ALDHhi HPC transplant recipients had a 
significant increase in total β cell mass, increased islet-specific proliferation, and showed 
improved response to glucose bolus injection in glucose tolerance tests. Furthermore, the 
culture-expanded ALDHhi HPC sub-population highly expressed pro-angiogenic 
transcripts by Affymetrix microarray, compared to the more differentiated ALDHlo HPC 
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subset. These findings suggest that HPC retaining high ALDH activity mediated the 
recovery from hyperglycemia, by stimulating an islet proliferative and islet vascularization. 
3.2 The HPC Lineage of ALDHhi UCB Progenitor Cells 
Expanded Efficiently in Culture. 
The HPC lineage of UCB ALDHhi cells was highly proliferative in culture. We achieved a 
total cell expansion of 2.3-fold, 20.7-fold, and 53.5-fold after 3, 6, and 9 days of culture, 
respectively. Culturing UCB-derived progenitor cells with hematopoietic cytokines results 
in a significant expansion in committed progenitor cells, with only a minimal expansion of 
primitive progenitor cells.2,3 Also, prolonged culture of UCB-derived progenitor cells 
under serum-free hematopoietic culture conditions, results in unwanted cellular 
differentiation. For instance, Bhatia et al.3 showed that, UCB-derived CD34+ cells 
expanded by 4-fold after 4 days of culture. These cells still expressed a primitive progenitor 
phenotype (CD34+/CD38-), and retained primitive SCID repopulating cells (SRC). 
Whereas, 9 days of culture resulted in an 8-fold expansion of total cells, but contained no 
CD34+/CD38- primitive progenitor cells, and loss of SRC function. We used relative 
ALDH activity to distinguish primitive hematopoietic progenitor cells, from more 
differentiated or committed progenitor cells. Similar to Bhatia et al., we found that the 
frequency of primitive progenitor cells declined as culture progressed.   
Furthermore, maturing progenitor cells in culture have been shown to secrete inhibitory 
factors such as TGF-β that limit the proliferation and expansion of more primitive 
progenitor cells.2,4 The TGF-β superfamily are pleotropic factors that regulate somatic 
tissue development, and regeneration.5 When TGF-β1 was added to liquid hematopoietic 
cultures it inhibited the proliferation of the primitive CD34+/CD38- cells, while stimulating 
the proliferation of the more mature CD34+/CD38+ cells.6 Studies investigating the 
mechanism by which TGF-β1 limits primitive progenitor cell expansion have shown that, 
TGF-β1 modulates CD-117 (c-kit receptor, binds SCF), TPO receptor, and FLT-3L 
receptor on primitive progenitor cells, thereby making them less responsive to these 
important supplemental factors ex vivo.7–9. Due to the accumulation of inhibitory soluble 
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factors in primary stem cell cultures, we first needed to determine the time point that 
yielded the highest number of primitive and presumably islet regenerative ALDHhi HPC. 
We found that 6 days of ex vivo expansion yielded the highest number of ALDHhi, 
ALDHhi/CD34+, and ALDHhi/CD133+ HPC. Thus, we further characterized the 
multipotent colony forming capacity in vitro and islet regenerative properties after i.v.-
transplantation using 6 day culture-expanded HPC subpopulations.    
3.3 Transplanted ALDHhi HPC Stimulated Islet 
Angiogenesis 
The endocrine pancreas in highly vascularized, it has 5-7 times more capillaries that the 
surrounding exocrine pancreas tissue.10 These islet capillary network provides glucose 
sensing pancreatic islets with nutrients, and oxygen.11 In addition, the islet capillary 
network is essential for optimal islet function. A dense islet capillary network is required 
for β cells to optimally sense blood glucose levels, and the fenestrations in the islet capillary 
endothelium is the most efficient way for insulin secreted by β cells to enter the systemic 
circulation.12 Furthermore, the islet capillary endothelium also supports β cell turnover. In 
an in vitro system, purified islet endothelial cells stimulated β cell proliferation primarily 
via the secretion of HGF.13 During pregnancy pancreatic β cells can undergo enhanced 
turnover. In vivo experiments, in pregnant rats showed that HGF levels were highly 
expressed in the islet capillary endothelium during peak stimulation of β cell 
proliferation.13 Another study showed that, laminins expressed on the basement membrane 
of the islet endothelium, binds to β1 integrin on β cells to stimulate β cell proliferation.14 
Collectively, these studies suggest that endothelial-endocrine axis plays an important role 
in supporting β cell function, and β cell turnover.  
Previously, we have shown that freshly isolated UCB cells with high ALDH activity 
contains pro-angiogenic progenitor cells that improved the perfusion of the ischemic limb, 
following transplantation into immunodeficient mice with acute hind-limb ischemia 
induced by femoral artery ligation.15 Freshly isolated UCB ALDHhi cells did not integrate 
into the murine vasculature, instead UCB ALDHhi cells homed selectively to areas of 
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inflammation in the ischemic limb, and stimulated endogenous murine capillary 
regeneration.15 Here we show that a subset of the culture-expanded progeny, ALDHhi HPC, 
significantly enhanced islet-specific capillary density in the STZ-treated mouse pancreas. 
VEGF is highly expressed in β cells, and is not expressed in extra-islet tissues.11,12,16,17 
Increased vascularization was specific to the islets, rather than extra-islet pancreatic tissue, 
suggesting that the VEGF is required for culture-expanded ALDHhi HPC to support an islet 
specific vascularization program, in the pancreas of STZ-NOD/SCID diabetic mice. 
Interestingly increased CD31+ capillary density was associated with an increased islet size 
and, islet cell proliferation, resulting in increased total β cell mass, and improved islet 
function. Thus, our data suggest that the transplantation of ALDHhi HPC improves islet 
function in STZ-NOD/SCID mice by re-establishing the endothelial-endocrine axis (Figure 
3.1). 
Intra-Pancreatic transplantation of freshly isolated UCB cells with high ALDH activity 
stimulated islet revascularization, and β cell proliferation in STZ-NOD/SCID mice, despite 
remarkably low level of engraftment (0.09 ± 0.03%, n=6 mice) of freshly isolated ALDHhi 
UCB cells in the pancreas, at day 42.1 However, iPan transplantation of ALDHhi UCB cells 
increased early recruitment of islet regenerative cells immediately surrounding 
regenerating islets at 7 days post transplantation. Presumably, many of these injected cells 
were lost by 1 month post-transplantation. Interestingly, iPan transplantation of freshly 
isolated UCB ALDHhi cells was more effective at improving systemic glycemia, compared 
to i.v. transplantation for UCB ALDHhi cells. Thus, we postulated that increased exposure 
of recovering islets to UCB ALDHhi cell secreted stimuli augmented a natural or 
endogenous islet regenerative process. Pancreatic β cells and ductal cells are known to 
secrete angiogenic growth factors such as vascular endothelial growth factor (VEGF), and 
chemokines such as stromal derived factor 1 (SDF-1), that recruit a pro-angiogenic cells 
specifically to STZ-damaged islets. In these studies human cells were not detected in the 
murine pancreas, at day 42, after i.v.-transplantation of culture-expanded ALDHhi HPC. 
Although early time course recruitment experiments have not yet been performed using 
expanded HPC subsets, we speculate i.v.-injected culture-expanded ALDHhi HPC were 
recruited to the damaged islets at early time points, surround these damaged islets and 
secrete factors that stimulate islet regeneration. However, due to the unfavourable 
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environment of the pancreas culture-expanded ALDHhi HPC may undergo apoptosis, or 
migrate away from the pancreas before day 42 leaving the regenerative effects observed 
appear short-term and not sustained. Thus, iPan transplantation of culture-expanded 
ALDHhi HPC may further increase early pancreas engraftment, and may augment the islet 
regenerative response via the initiation of islet regenerative programs. These important 
experiments are planned for future studies 
3.4 ALDHhi HPC Secrete Cytokines Involved in 
Angiogenesis   
The mRNA levels of the secreted proteins Semaphorin 4A (SEMA4A), Angiopoietin 2 
(ANGPT2), and Milk Fat Globule-EGF factor 8 (MFG-E8) were higher in culture-
expanded ALDHhi HPC compared to ALDHlo HPC. The proteins encoded by these 
transcripts are all involved in supporting vascular endothelial growth factor-A (VEGFA) 
mediated angiogenesis. MFG-E8 also known as lactadherin has been shown to interact with 
αvβ3 integrins on endothelial cells, and cooperates with VEGF signaling to activate a potent 
pro-angiogenic pathway.18 Interestingly, in the hind-limb ischemic model injection of anti-
MFG-E8 blocked VEGFA induced angiogenesis.18 The transcript of ANGPT2 was also up 
regulated in culture-expanded ALDHhi HPC. Studies have shown that, ANGPT2 is a 
complex regulator of vascular remodelling that supports both vessel sprouting and vessel 
regression. In the setting of angiogenic sprouting ANGPT2 is rapidly induced with VEGF, 
whereas in the setting of vascular regression, ANGPT2 is induced in the absence of 
VEGF.19–24 Studies in mice lacking ANGPT2 shows that, ANGPT2 is essential for 
postnatal vascular remodeling of the eye. The retina of post natal mice lacking ANGPT2, 
was devoid of peripheral vessels, and had minimal central vasculature.25 Pancreatic β cells 
express high levels of VEGF.12,16,17 It is plausible that MFG-E8, and ANGPT2 secreted by 
ALDHhi HPC stimulate islet vascularization, by supporting a VEGF dependent angiogenic 
program.  
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Figure 3.1 Working Model. Schematic of the proposed mechanism by which ALDHhi 
HPC improves islet function. Our data suggest that transplanted ALDHhi HPC surround 
damaged islets and secrete factors such as SEMA4A, ANGPT2, and MFGE8 that supports 
islet angiogenesis, to re-establishing the endothelial-endocrine axis. HGF secreted by 
endothelial cells, or laminins expressed on the basement membrane of endothelial cells 
support β cell proliferation, which results in an increased islet size, and β cell mass.   
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Finally, the transcript of SEMA4A was up-regulated in culture-expanded ALDHhi HPC. 
SEMA4A has been shown to act on PlexinD1 receptors, to stimulate the release of VEGFA 
from macrophages.26 The VEGFA subsequently secreted from macrophages, after SEM4A 
stimulation exerted a pro-angiogenic effect on endothelial cells in vitro, by activating the 
P13/AKT pathway in endothelial cells. Furthermore, the VEGFA produced by accessory 
macrophages stimulated angiogenesis in the in vivo chorioallantonic membrane (CAM) 
assay. Interestingly, although the NOD/SCID is completely depleted of T and B-
lymphocyte activity, the NOD/SCID does retain residual macrophage and NK-cells of the 
innate immune system Thus, residual mouse macrophages may be recruited to the pancreas 
after STZ-induced islet injury in our model and may act as accessory cells in the islet 
regenerative process.27 Adoptive transfer of M2 macrophages have been shown to protect 
NOD mice from developing diabetes, by homing to the inflamed pancreas and secreting 
anti-inflammatory cytokines.27 SEM4A produced by ALDHhi cells may act on the 
PlexinD1 receptors on these macrophages to stimulate VEGFA release, which 
subsequently supports angiogenesis in regenerating islets of STZ-treated diabetic mice. 
Collectively, these data suggests that the pro-angiogenic microenvironment established in 
the pancreas of STZ-NOD/SCID diabetic mice after the transplantation of ALDHhi HPC 
may be beneficial to islet regeneration through the activity of murine macrophage 
intermediates.      
3.5 Increasing the Number of Primitive Culture-
Expanded HPC for a Cell Based Therapy to Treat 
Diabetes 
In this study we show that culture-expanded HPC retaining a primitive progenitor 
phenotype (ALDHhi HPC) stimulate endogenous islet regeneration in STZ-NOD/SCID 
diabetic mice. Conversely, more differentiated ALDHlo HPC or even unsorted Bulk HPC 
could not stimulate similar regenerative processes in situ. For hematopoietic 
transplantation applications using UCB cells, researchers have attempted to increase the 
number primitive HPC during the ex vivo expansion of the HPC lineage. Recent success 
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has been achieved by, adding small molecules to hematopoietic culture conditions, and 
expanding UCB progenitor cells in a bioreactor using a batch fed system.28–34 
For instance, Boitano et al.29 have found that StemRegenin1 (SR1)-an aryl hydrocardon 
receptor antagonist-promotes the overall expansion of human HPC. When added to serum 
free media supplemented with hematopoietic growth factors this compound increased the 
number of primitive CD34+ cells by 73-fold, when compared to cells cultured with growth 
factors alone (basal culture conditions). Importantly, the number of SRC that retain both 
multilineage and long-term engraftment potential, increased by 8-fold compared to basal 
culture conditions.  
ALDH is highly expressed in HPC, and is a critical enzyme in the biosynthesis of RA. The 
addition of RA to hematopoietic culture (SCF, FLT3L, TPO), resulted in HPC 
differentiation.32 Chute et al.32 found that inhibiting ALDH with the small molecule DEAB 
in hematopoietic culture (SCF, FLT-3L, TPO) decreased RA signaling in HPC. 
Furthermore, when DEAB was added to hematopoietic the number of primitive SRC 
increased by 6-fold compared to cells cultured in basal hematopoietic culture conditions.          
Csaszar et al.28 developed an automated controlled fed-batch dilution approach to expand 
UCB progenitor cells. UCB cells were cultured in hematopoietic conditions in a bioreactor, 
and new media was added at a constant flow rate to the hematopoietic culture. Using this 
approach the factors that inhibit the growth of primitive progenitor cells such as TGF-β are 
constantly diluted and removed from the culture microenvironment. As a result, the number 
of CD34+ cells was increased by 80-fold, when compared to UCB cells expanded under 
basal (non-batch fed) conditions. In addition, the number of SRC increased by 11-fold 
compared to control conditions. Thus, the number of primitive HPC available to treat 
diabetes using the stimulation of endogenous islet regeneration could be increased in the 
future by adding small molecules to hematopoietic culture conditions or by expanding 
UCB ALDHhi progenitor cells using a batch-fed a bioreactor system. 
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3.6 Clinical Implications 
Our data outlines a clinically applicable regenerative approach for the treatment of 
diabetes. Allogeneic human UCB progenitor cells can be isolated in a clinically relevant 
manner using ALDH activity, and the HPC lineage of the ALDHhi UCB cells can be 
expanded without serum or xenobiotic agents in clinically applicable fashion. High ALDH 
activity can subsequently be used to re-select cells with islet regenerative properties after 
culture, and prior to transplantation. Furthermore, the number of primitive HPC with islet 
regenerative properties can be further increased by adding clinically applicable small 
molecules to hematopoietic cultures, or by expanding hematopoietic cells using a batch-
fed bioreactor system.   
In order for culture=expanded ALDHhi HPC to be a plausible therapy for type-1 diabetes, 
the issue of continued autoimmune destruction of regenerated β cells must be addressed. 
Solvason et al.35 demonstrated that a plasmid DNA vaccine encoding mouse proinsulin II 
(BHT-3021) reduced the incidence of diabetes, when administered into NOD mice both 
before the onset of hyperglycemia (prophylactically), and after the onset of hyperglycemia 
(therapeutically). BHT-3021 recently completed phase I clinical trials in type-1 diabetic 
patients diagnosed within the past 5 years.36 No adverse events were reported in subjected 
treated with BHT-3021. In fact, the subjects administered with BHT-3021 demonstrated 
improved c-peptide level compared to placebo treated subjects even without the stimulation 
of endogenous islet regenerative processes. In addition, the frequency of proinsulin reactive 
CD8+ T-cells declined in BHT-3021 treated subjects. This trial clearly shows that, BHT-
3021 reduces frequency of CD8+ T cells reactive to proinsulin, while preserving c-peptide 
levels over the course of dosing. However, the β cell mass of type 1 diabetic patients is 
already reduced by 70-80% at the time of diagnosis.37 Thus, ALDHhi HPC that increases β 
cell mass and endogenous glucose secretion, together with BHT-3021 that prevents further 
β cell deletion and preserves β cell function may represent a highly rationalized potential 
strategy to treat type 1 diabetes.   
As mentioned earlier, the Medalist study revealed that diabetic patients with long standing 
diabetes demonstrate residual β cell function.38 Thus, culture-expanded ALDHhi HPC from 
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widely accessible UCB samples can be potentially utilized to stimulate endogenous β cell 
regeneration in diabetic patients with long standing diabetes.  
Transplantation of culture-expanded ALDHhi HPC may also represent a potential strategy 
for the therapy for type 2 diabetic patients, who have a decreased β cell mass, and insulin 
resistance at advanced stages of the disease.39 Although the issue of insulin resistance in 
these patients will still need to be addressed by diet, exercise, and hypoglycemic agents, 
culture-expanded ALDHhi HPC can aid in restoring β cell mass, and increase the insulin 
available to meet metabolic demand, essentially “tipping the balance” in favour of islet 
regeneration versus metabolic destruction in end-stage (insulin-dependent). We are 
currently generating preclinical xenotransplantation models of type 2 diabetes using the 
longer-lived NOD/SCID gamma (NSG) xenotransplantation model combined with high fat 
diet and low dose STZ monotherapy  
Our study has several limitation that needs to be addressed before our findings can be 
applied to the clinic. Firstly, the glucometer we used for glucose tolerance testing was only 
able to detect a maximum glucose concentration of 33mmol/L. Therefore, to better 
characterize the glucose tolerance of mice transplanted with ALDHlo HPC, and ALDHhi 
HPC a glucometer with a higher range is required as readings in the mice were maximal 
after the injection of a glucose bolus. Alternatively, mouse blood samples could be diluted 
prior to glucose measurement to ensure that readings were within the range of 
quantification by the glucometer, resulting in more accurate glucose tolerance 
measurements. Also, type 1 diabetes involves the auto-immune destruction of β cells, 
whereas our diabetic mouse model involves the chemical destruction of β cells to induce 
hyperglycemia in immunodeficient NOD/SCID mice. Therefore, β cell regeneration is 
being studied in a model free of any autoimmune attack on islets. In addition, type 2 
diabetes is a metabolic disease usually associated with obesity. Our NOD/SCID diabetic 
mouse model only depicts the hyperglycemia of type 2 diabetes, thus islet regeneration is 
studied in the absence of many inflammatory cytokines and metabolites associated with 
obesity. Finally, studying the islet regenerative properties of human cells is important, 
because these cells may eventually be used in human clinical trials. However, due to 
86 
 
species incompatibilities, transplantation of human progenitor cells into a mouse model 
may not fully recapitulate the regenerative capacity of human progenitor cells.  
3.7 Future Directions 
BHT-3201 preserves β cell function, while ALDHhi HPC stimulates endogenous islet 
regeneration. Studies could be performed in NOD mice, in order to determine if these 
therapeutic agents can work in combination to treat type 1 diabetes. In order to determine 
if ALDHhi HPC can stimulate endogenous islet regeneration in type 2 diabetic milieu, 
ALDHhi HPC could be transplanted into NSG type 2 diabetic mouse model. After 
transplantation islet function, β cell mass, and islet vascular density needs to be assessed.        
By microarray analysis of ALDHhi HPC and ALDHlo HPC sub-populations this study 
identified MFG-E8, SEMA4A, and ANGPT2 to be potentially involved in stimulating islet 
specific angiogenesis. To further gain insight into the islet regenerative niche these 
microarray hits needs be confirmed by performing ELISA on the supernatants or by 
western blot on cell lysates from culture-expanded ALDHhi HPC and ALDHlo HPC subsets. 
In order determine if these secreted proteins are directly involved in islet revascularization, 
ALDHhi HPC needs to be intravenously transplanted with either MFG-E8, or SEMA4A, 
or ANGPT2 antibodies individually or with a combination of these antibodies, and islet 
function, β cell mass, and islet vascular density must be assessed. Further understanding 
the regenerative niche will aid in the optimization of a cellular regenerative therapy using 
expanded HPC therapy to promote islet function as a part of a multidisciplinary rational 
approach to treat both type 1 or type 2 diabetes.      
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 My project focused on the aberrant expression of toll like receptors in AML.  
 I performed flow cytometry to determine the expression of toll-like receptors 
in AML cell lines as well as patient samples. 
 I also optimized a stable transfection protocol for the over-expression of the 
TLRs in HEK 293 cells. 
 My research was fully funded by Canadian Institutes of Health and Research 
(CIHR) program in Biological Therapeutics, as well as the Department of 
Medical Biophysics at the University of Toronto.  
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September 2009-May 2010: Work-Study Student in Dr. Chandan Chakraborty’s 
Lab, Department of Pathology, Schulich School of Medicine and Dentistry, The 
University of Western Ontario. 
 Lab focuses on intracellular signal transduction mechanisms which play an 
important role in agonist induced cellular migration 
 Assisted MSc and PhD students with cell migration assays, PCR, and gel 
electrophoresis.     
 
 
Section 3: Publications 
 
Journal Publications 
 
Bell GI, Seneviratne A, Nasri GN, Hess DA. TRANSPLANTATION MODELS TO 
CHARACTERIZE THE MECHANISM OF STEM CELL INDUCED ISLET 
REGENERATION. In Press at Current Protocols in Stem Cell Biology. April 10, 2013, CP-
13-0022.R1.  
 
My role in this project was to design and write the manuscript. Overall, my contribution to 
the team effort for this publication was 30%. 
 
Sukhai MA, Prabha S, Hurren R, Rutledge AC, Lee AY, Sriskanthadevan S, Sun H, Wang 
X, Skrtic M, Seneviratne A, Cusimano M, Jhas B, Gronda M, Maclean N, Cho EE, 
Spagnuolo PA, Sharmeen S, Gebbia M, Urbanus M, Eppert K, Dissanayake D, Jonet A, 
Dassonville-Klimpt A, Li X, Datti A, Ohashi PS, Wrana J, Rogers I, Sonnet P, Ellis WY, 
Corey SJ, Eaves C, Minden MD, Wang JC, Dick JE, Nislow C, Giaever G, Schimmer AD. 
LYSOSOMAL DISRUPTION AS A THERAPEUTIC STRATEGY FOR ACUTE MYELOID 
LEUKEMIA. (2013) The Journal of Clinical Investigation. 123: 315-328.    
 January 2013 JCI Cover Article 
 Editor’s Pick: highlighted in JCI Impact Digest, January 2013 (inaugural edition) 
 Named one of the Canadian Cancer Society’s top 10 cancer research stories for 
2012: 
http://www.cancer.ca/Canada-wide/About%20us/Media%20centre/CW-
Media%20releases/CW-2012/Top%2010%20Society-
funded%20research%20of%202012.aspx?sc_lang=en 
 Highlighted in the Toronto Star, January 03, 2013: 
http://www.thestar.com/specialsections/cancerresource/article/1309484--hope-in-10-
cancer-breakthroughs 
 
My role in this project was to design and perform experiments to determine if the anti-
malarial mefloquine induced the production of ROS in AML cells, and synergistically 
increased ROS production when combined with 3 members of the artmisinin family of anti-
malarials. To further explore the anti-leukemic activity of lysosomal disruption, I evaluated 
the ability of the known lysosomal disrupter L-leucine-leucine methyl ester (LeuLeuOMe) 
to produce ROS in AML cells. My contribution to the team effort for this publication was 
5%. 
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Abstracts for Publication at International Conferences: 
 
Seneviratne A, Bell GI, Sherman S, Putman DM, Hess DA. A Sub-Population of 
Expanded Hematopoietic Progenitor Cells that Retain High Aldehyde Dehydrogenase 
Demonstrates Islet Regenerative Properties. Accepted for a poster presentation by the 
Canadian Stem Cell Network for presentation at the 2nd Annual Till and McCulloch 
Meeting, October 23-25, 2013 Banff, AB. Recipient of Stem Cell Network Travel Award 
2013.   
 
Seneviratne A, Bell GI, Putman DM, Hess DA. A Sub-Population of Expanded 
Hematopoietic Progenitor Cells that Retain High Aldehyde Dehydrogenase Activity 
Improves Islet Function. Accepted for a poster presentation by the International Society of 
Stem Cell Research for presentation at the 11th Annual ISSCR Conference Boston, MA. 
Recipient Ontario Stem Cell Initiative travel award 2013.  
 
Putman DM, Hewitt M, Seneviratne A, Hess DA. Ex vivo Expanded Human Umbilical 
Cord Blood Myeloid Progenitor Cells Stimulate Vascular Regeneration.  
Accepted for a poster presentation by the International Society of Stem Cell Research for 
presentation at the 11th Annual ISSCR Conference Boston, MA.  
 
Seneviratne A, Bell GI, Putman DM, Hess DA. The Phenotype and Islet Regenerative 
Functions of ex vivo Expanded Hematopoietic Progenitor Cells. Accepted for a poster 
presentation at the 1st Annual M3: Mostly Mammals in Montreal Meeting, March 21-23, 
2011, Montreal, QB.   
 
Sukhai MA, Hurren R, Rutledge A, Livak B, Wang X, Seneviratne A, Cusimano M, 
Gebbia M, Skrtic M, Sun H, Gronda M, Spagnuolo P, Urbanus M, Eppert K, 
Dissanayake D, Li X, Sun T, Vizeacoumar F, Datti A, Ohashi P, Wrana J, Rogers I, 
Minden MD, Wang J, Dick JE, Corey S, Nislow C, Giaever G, Schimmer AD. 
Lysosomal disruption selectively targets leukemia cells and leukemia stem cells through 
a mechanism related to increased reactive oxygen species production. Accepted for oral 
presentation by the American Society of Hematology for presentation at the 53rdASH 
Annual Meeting, December 10-13, 2011, Sam Diego, CA. 
 
Sukhai MA, Li X, Hurren R, Wang X, Skrtic M, Sun H, Gronda M, Seneviratne A, 
Dissanayake D, Chow S, Bremner R, Hedley D, Minden MD, Ohashi P, Schimmer AD. 
The Anti-Malarial Mefloquine Demonstrates Preclinical Activity In Leukemia and 
Myeloma, and Is Dependent Upon Toll-Like Receptor Signaling for Its Cytotoxicity. 
Accepted for Oral Presentation by the American Society of Hematology for presentation 
at the 52nd ASH Annual Meeting, December 04-07, 2010, Orlando, FL. 
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Manuscripts in Preparation 
 
Seneviratne A, Bell GI, Cooper T, Sherman S, Putman DM, Hess DA. A Sub-Population 
of Expanded Hematopoietic Progenitor Cells that Retain High Aldehyde Dehydrogenase 
Demonstrates Islet Regenerative Properties.   
 
My role in this project is project lead. I am significantly involved in collecting, interpreting 
and analyzing data, and drafting the manuscript. Overall, my contribution to the team 
effort for this publication is 95%. As of now this manuscript is 70% complete. 
 
 
Putman DM, Hewitt M, Seneviratne A, Hess DA. Ex vivo Expanded Human Umbilical 
Cord Blood Myeloid Progenitor Cells Stimulate Vascular Regeneration.  
 
My role in this project is to design and perform experiments to characterize the phenotype 
of hematopoietic progenitor cells derived from umbilical cord blood cells with high 
aldehyde dehydrogenase activity. Overall, my contribution to the team effort for this 
publication is 15%. As of now this manuscript is 98% complete. 
 
Patel P, Brooks C, Seneviratne A, Hess DA and Séguin CA. Investigating 
Microenvironmental Regulation of Human Chordoma Cell Behaviour.  
 
My role in this project is to design and perform experiments to characterize the phenotype 
of human chordoma cells cultured in hypoxic or normoxic conditions. Overall, my 
contribution to the team effort for this publication is 5%. As of now this manuscript is 80% 
complete. 
 
 
 
 
 
Section 4: Presentations 
 
Ayesh Seneviratne, Gillian I. Bell, Stephen Sherman, David M. Putman, David A. Hess. A 
Sub-Population of Expanded Hematopoietic Progenitor Cells that Retain High Aldehyde 
Dehydrogenase Activity Improves Islet Function by Stimulating Endogenous Islet 
Regeneration and Vascularization. Accepted for poster presentation by the Molecular 
Medicine Group at the Robarts Research Institute for presentation at the 1st annual 
Robarts Research Retreat, Bellamere Winery, June 9, 2014. 
 
Ayesh Seneviratne, Gillian I. Bell, Stephen Sherman, David M. Putman, David A. Hess. A 
Sub-Population of Expanded Hematopoietic Progenitor Cells that Retain High Aldehyde 
Dehydrogenase Activity Improves Islet Function by Stimulating Endogenous Islet 
Regeneration and Vascularization. The Collaborative Graduate Program in 
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Developmental Biology 6th annual Developmental Biology research day, Civic Garden 
complex, May 30, 2014. 
 
Ayesh Seneviratne, Gillian I. Bell, Stephen Sherman, David M. Putman, David A. Hess. A 
Sub-Population of Expanded Hematopoietic Progenitor Cells that Retain High Aldehyde 
Dehydrogenase Activity Improves Islet Function by Stimulating Endogenous Islet 
Regeneration and Vascularization. Schulich School of Medicine and Dentistry London 
Health research day, London Convention Centre, March 18, 2014.  
 
Ayesh Seneviratne, Gillian I. Bell, Stephen Sherman, David M. Putman, David A. Hess. A 
Sub-Population of Expanded Hematopoietic Progenitor Cells that Retain High Aldehyde 
Dehydrogenase Demonstrates Islet Regenerative Properties. Schulich School of Medicine 
and Dentistry 4th annual Diabetes research day, St. Joseph’s Hospital, November 12, 2013.  
 
Ayesh Seneviratne, Gillian I. Bell, Stephen Sherman, David M. Putman, David A. Hess. A 
Sub-Population of Expanded Hematopoietic Progenitor Cells that Retain High Aldehyde 
Dehydrogenase Demonstrates Islet Regenerative Properties. Deparment of Physiology and 
Pharmacology Gowdey research day, Western University, November 4, 2013. 1st place 
award Recipient for the best poster. 
 
Ayesh Seneviratne, Gillian I. Bell, Stephen Sherman, David M. Putman, David A. Hess. A 
Sub-Population of Expanded Hematopoietic Progenitor Cells that Retain High Aldehyde 
Dehydrogenase Improves Islet Function. The Collaborative Graduate Program in 
Developmental Biology 5th annual Developmental Biology research day, Civic Garden 
complex, May 30, 2013 
 
Ayesh Seneviratne, Gillian I. Bell, Heather C. Broughton, David A. Hess. The Phenotype and 
Islet Regenerative Functions of ex vivo Expanded Hematopoietic Progenitor Cells. Schulich 
School of Medicine and Dentistry London Health research day, London Convention 
Centre, March 19, 2013.  
 
Ayesh Seneviratne, Gillian I. Bell, Heather C. Broughton, David A. Hess. The Phenotype and 
Islet Regenerative Functions of ex vivo Expanded Hematopoietic Progenitor Cells. Schulich 
School of Medicine and Dentistry 3rd annual diabetes research day, St. Joseph’s Hospital, 
November 13, 2012. 2nd place award Recipient for the best poster.  
 
Ayesh Seneviratne, Gillian I. Bell, David M. Putman, David A. Hess. The Phenotype and Islet 
Regenerative Functions of ex vivo Expanded Hematopoietic Progenitor Cells. Deparment of 
Physiology and Pharmacology Stevenson research day, Western University, November 6, 
2012. 2nd place award Recipient for the best poster. 
 
Ayesh Seneviratne, Gillian I. Bell, Heather C. Broughton, David A. Hess. The Effect of 
Transplanted Human Hematopoietic Progenitor Lineage on β cell Proliferation and Islet 
Regeneration. Deparment of Physiology and Pharmacology annual 4th year thesis 
student research day, Western University, April 2, 2012.  
  
Ayesh Seneviratne, Maria Cusimano, Mahadeo A Sukhai, Bozena Livak, Angela 
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Rutledge, Rose Hurren, Paul Spagnuolo, Aaron D. Schimmer. Lysosomal Disruption 
Selectively Targets Leukemia Cells Through a Mechanism Related to Increased ROS 
Production. Deparment of Physiology and Pharmacology Gowdey research day, 
Western University, November 8, 2011.  
 
Ayesh Seneviratne, Maria Cusimano, Mahadeo A Sukhai, Bozena Livak, Angela 
Rutledge, Rose Hurren, Paul Spagnuolo, Aaron D. Schimmer. Lysosomal Disruption 
Selectively Targets Leukemia Cells Through a Mechanism Related to Increased ROS 
Production. Department of Medical Biophysics summer student presentation, 
University of Toronto, August 18, 2011.  
 
Ayesh Seneviratne, Mahadeo A. Sukhai, Joyce Sun, Xiaoming Li, Aaron D. Schimmer. 
Aberrant Expression of Toll-Like Receptors in Acute Myelogenous Leukemia. 
Department of Medical Biophysics summer student presentation, University of 
Toronto, August 13, 2010.  
 
Ayesh Seneviratne, Mahadeo A. Sukhai, Joyce Sun, Xiaoming Li, Aaron D. Schimmer. 
Aberrant Expression of Toll-Like Receptors in Acute Myelogenous Leukemia  
CIHR Biological Therapeutics summer student presentation, July 26, 2010.  
 
 
Section 5: Teaching Experience 
 
September 2012-Present: Teaching Assistant Physiology 3130Y, Western University 
 Responsible for facilitating the pre-lab tutorials, post lab tutorials, and helping 
students to complete their lab.  
 
September 2009-May 2010: Tutor for Frontier College, an institution that helps 
underprivileged individuals with their academics. 
 Helped children from ages 8-13 with reading and assignments  
 
Sept 2007-June 2008: Peer Tutor- Applewood Heights Secondary School, 
Mississauga Ontario. 
 Mentored and guided grade 9 and 10 students to achieve better academic 
result 
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Section 6: Supervisory and Mentorship Experience 
 
September 2013-Present  Mr. Tyler Cooper, 4th year Research 
Student, Department of Biology, 
University of Western Ontario, London, 
Ontario. Project Title: The Phenotype 
and Colony Forming Capacity of 
Hematopoietic Progenitor cells 
Expanded by the Modulation of the 
Retinoic Acid Pathway.  
May 2013-August 2013 Mr. Stephen Sherman, Summer Student 
Robarts Research Institute, London, 
Ontario 
 
 
 
 
 
Section 7: Technical Experience 
 
 Proficient in vivo procedures such as: 1) intravenous transplantation, 
intrapancreatic transplantation procedures; 2) subcutaneous, intramuscular, and 
intraperitoneal injection procedures; 3) Intravenous, and intracardiac blood 
collection procedures.    
 Proficient in vitro assays such as: cell imunotyping using flow cytometry, tissue 
culture, transfection methodologies, immunohistochemistry, colony formation 
unit assay   
 
 
 
Section 8: Academic Accomplishments and Awards 
Master’s 
 
Studentships: 
 Recipient, Ontario graduate scholarship (2013-2014; $15,000) 
 Recipient, Ontario Graduate Scholarship (2012-2013; $15,000). 
 
Travel Awards: 
 Recipient, Stem Cell Network travel award (2013) 
 Recipient, Ontario Stem Cell Initiative travel award (2013; $ 1,000) 
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Poster Awards: 
 
 Recipient, 1st  place award Recipient in the Category of Endocrinology and 
Reproductive Physiology at the Deparment of Physiology and Pharmacology 
Gowdey research day, Western University (November 4, 2013; $250).  
 Recipient, 2nd place award for the best poster at the Schulich School of Medicine and 
Dentistry annual diabetes research day, St. Joseph’s Hospital (November 13, 2012; 
$200).  
 Recipient, 2nd  place award Recipient in the Category of Endocrinology and 
Reproductive Physiology at the Deparment of Physiology and Pharmacology 
Stevenson research day, Western University (November 6, 2012; $100).  
 
 
Undergraduate  
 
Studentships: 
 Recipient, University of Toronto Summer Undergraduate Studentship Award 
(2011; $2400).   
 Recipient, University of Toronto Summer Undergraduate Studentship Award 
(2010; $2400).    
 Summer Studentship, CIHR strategic training program in biological therapeutics 
(2010). 
 
Scholarships:  
 Recipient, Richard Ivey Foundation International Exchange Scholarship   
(2010/11; $5,000). 
 Queen Elizabeth Scholarship (2008-2012; $3,500/yr). 
  University of Western Ontario Scholarship of Excellence (2008/09; $2000).  
 
Academic Accomplishments:  
 University of Western Ontario Dean’s Honours’ list (2008-2012).  
 University of Western Ontario Scholar (2008-2012). 
 
Secondary School 
 Ontario Scholar (2007-2008) 
 Applewood Heights Secondary School Honors list (2006-2008) 
 Proficiency, Introduction to Anthropology, Sociology, and Psychology (2006/07) 
 
 
 
 
